<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062854" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of childhood extracranial germ cell tumors.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Childhood Extracranial Germ Cell Tumors (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000043493">childhood extracranial germ cell tumor</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Childhood Extracranial Germ Cell Tumors Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Childhood Extracranial Germ Cell Tumors Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000043493">childhood extracranial germ cell tumor</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Childhood Extracranial Germ Cell Tumors (GCTs)</Title><Para id="_3">Cancer in children and adolescents is rare, although the overall incidence of childhood cancer has slowly increased since 1975.<Reference refidx="1"/>  Children and
adolescents with cancer should be referred to medical centers that have a
multidisciplinary team of cancer specialists with experience treating the
cancers that occur during childhood and adolescence.  This multidisciplinary team approach incorporates the skills of the following health care professionals and others to ensure that children receive treatment, supportive care, and rehabilitation that will achieve optimal survival and quality of life:</Para><ItemizedList id="_591" Style="bullet"><ListItem>Primary care physicians.</ListItem><ListItem>Pediatric surgeons.</ListItem><ListItem>Radiation oncologists. </ListItem><ListItem>Pediatric medical oncologists and hematologists.</ListItem><ListItem>Rehabilitation specialists.</ListItem><ListItem>Pediatric nurse specialists.</ListItem><ListItem>Social workers.</ListItem><ListItem>Child life professionals.</ListItem><ListItem>Psychologists.</ListItem></ItemizedList><Para id="_120">Guidelines for pediatric cancer centers and their role in the treatment of
pediatric patients with cancer have been outlined by the American Academy of
Pediatrics.<Reference refidx="2"/>  At these pediatric cancer centers, clinical trials are
available for most of the cancer types that occur in children and
adolescents, and the opportunity to participate in these trials is offered to
most patients and families.  Clinical trials for children and adolescents with
cancer are generally designed to compare potentially better therapy with
therapy that is currently accepted as standard.  Most of the progress
made in identifying curative therapies for childhood cancers has been achieved
through clinical trials.  Information about ongoing clinical trials is
available from the <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</ExternalRef>.</Para><Para id="_121">Dramatic improvements in survival have been achieved for children and adolescents with cancer.<Reference refidx="3"/> Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.<Reference refidx="3"/> During the period from 2002 to 2010, cancer mortality continued to decrease by 2.4% per year for children and adolescents with acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin and non-Hodgkin lymphoma, neuroblastoma, central nervous system tumors, and gonadal tumors, as compared with the period from 1975 to 1998 (plateauing from 1998 to 2001).<Reference refidx="3"/>  Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment.  (Refer to the PDQ summary on <SummaryRef href="CDR0000343584" url="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</SummaryRef>     for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.)</Para><Para id="_433">GCTs arise from primordial germ cells, which migrate during embryogenesis from the yolk sac through the mesentery to the gonads.<Reference refidx="4"/><Reference refidx="5"/> Childhood extracranial GCTs   can be divided into the following two types:</Para><ItemizedList id="_434" Style="bullet"><ListItem>Gonadal.</ListItem><ListItem>Extragonadal. </ListItem></ItemizedList><Para id="_435">Most childhood extragonadal GCTs arise in midline sites (i.e., sacrococcygeal, mediastinal, and retroperitoneal); the midline location may represent aberrant embryonic migration of the primordial germ cells.</Para><Para id="_436">Childhood extracranial GCTs are broadly classified as the following:</Para><ItemizedList id="_437" Style="bullet"><ListItem>Mature teratomas.</ListItem><ListItem>Immature teratomas.</ListItem><ListItem>Malignant GCTs.</ListItem></ItemizedList><Para id="_438">GCTs comprise a variety of histologic diagnoses and can also be divided into the following histologic types:</Para><ItemizedList id="_439" Style="bullet"><ListItem>Germinoma.<ItemizedList id="_440" Style="dash"><ListItem>Germinoma.</ListItem><ListItem>Dysgerminoma (ovary).</ListItem><ListItem>Seminoma (testis).</ListItem></ItemizedList></ListItem><ListItem>Nongerminoma. <ItemizedList id="_441" Style="dash"><ListItem>Teratoma (mature and immature).</ListItem><ListItem>Yolk sac tumor (endodermal sinus tumor).</ListItem><ListItem>Choriocarcinoma.</ListItem><ListItem>Embryonal carcinoma.</ListItem><ListItem>Gonadoblastoma.</ListItem><ListItem>Mixed GCT (contains more than one of the histologies above).</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_584">(Refer to the PDQ summary on <SummaryRef href="CDR0000712041" url="/types/brain/hp/child-cns-germ-cell-treatment-pdq">Childhood Central Nervous System Germ Cell Tumors
Treatment</SummaryRef> for information about the treatment of intracranial germ cell tumors.)</Para><SummarySection id="_442"><Title>Incidence</Title><Para id="_4">Childhood GCTs are rare in children younger than 15
years, accounting for   approximately 3% of cancers in this age
group.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/> In the fetal/neonatal age group, most extracranial GCTs are benign teratomas occurring at midline locations, including sacrococcygeal, retroperitoneal, mediastinal, and cervical regions.  Despite the small percentage of malignant teratomas that occur in this age group,  perinatal tumors have a high morbidity rate caused by hydrops fetalis and premature delivery.<Reference refidx="9"/><Reference refidx="10"/> </Para><Para id="_443">Extracranial GCTs (particularly testicular GCTs) are much more common among  adolescents aged 15 to 19 years, representing
approximately 14% of cancers in this age group.  </Para><Para id="_444">The incidence of extracranial GCTs by 5-year age group and  gender is shown in Table 1.
</Para><Table id="_164">
<Title>Table 1.  Incidence of Extracranial Germ Cell Tumors by Age Group and Gender (per 10<Superscript>6</Superscript> population)<Superscript>a</Superscript></Title>
<TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="20.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="20.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="20.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="20.00%"/><ColSpec ColName="col5" ColNum="5" ColWidth="20.00%"/><THead><Row><entry/><entry>0–4 years</entry><entry>5–9 years</entry><entry>10–14 years </entry><entry>15–19 years</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Rates are per 1 million children from 1986 to 1995 for the nine Surveillance, Epidemiology, and End Results regions plus
Los Angeles. </entry></Row></TFoot><TBody><Row><entry>Males</entry><entry Align="Center" Valign="Middle">7 </entry><entry Align="Center" Valign="Middle">0.3  </entry><entry Align="Center" Valign="Middle">1.4  </entry><entry Align="Center" Valign="Middle">31 </entry></Row><Row><entry>Females</entry><entry Align="Center" Valign="Middle">5.8 </entry><entry Align="Center" Valign="Middle">2.4 </entry><entry Align="Center" Valign="Middle">7.8  </entry><entry Align="Center" Valign="Middle">25.3 </entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_13"><SectMetaData><SpecificDiagnosis ref="CDR0000043493">childhood extracranial germ cell tumor</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Histologic Classification of Childhood Extracranial GCTs</Title><Para id="_14">Childhood extracranial GCTs comprise a variety of histologic
diagnoses and can be broadly classified as the following: 
</Para><ItemizedList id="_445" Style="bullet"><ListItem><SummaryRef href="CDR0000062854#_130" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Mature teratomas</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_132" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Immature teratomas</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_134" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Malignant GCTs</SummaryRef>.</ListItem></ItemizedList><Para id="_446">The histologic properties of these tumors are heterogeneous and vary by primary tumor site and the gender and age of the patient.<Reference refidx="11"/><Reference refidx="12"/> Histologically identical GCTs that arise in younger children have different biological characteristics from those that arise in adolescents and young adults.<Reference refidx="13"/></Para><SummarySection id="_130"><Title>Mature teratomas</Title><Para id="_131">Mature teratomas usually occur in the ovary or at extragonadal locations. They are the most common histological subtype of childhood GCT.<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/>  Mature teratomas usually contain well-differentiated tissues from the ectodermal, mesodermal, and endodermal germ cell layers, and any tissue type may be found within the tumor.  </Para><Para id="_447">Mature teratomas are benign, although some mature teratomas may secrete enzymes or hormones, including insulin, growth hormone, androgens, and prolactin.<Reference refidx="17"/><Reference refidx="18"/></Para></SummarySection><SummarySection id="_132"><Title>Immature teratomas</Title><Para id="_133">Immature teratomas contain tissues from the ectodermal, mesodermal, and endodermal germ cell layers, but immature tissues, primarily neuroepithelial, are also present.  Immature teratomas are graded from 0 to 3 on the basis of the amount of immature neural tissue found in the tumor specimen.<Reference refidx="19"/> Tumors of higher grade are more likely to have foci of yolk sac tumor.<Reference refidx="20"/> Immature teratomas may be classified as malignant tumors. </Para><Para id="_448">Immature teratomas occur primarily in young children at extragonadal sites and in the ovaries of girls near the age of puberty, but there is no correlation between tumor grade and patient age.<Reference refidx="20"/><Reference refidx="21"/> Some immature teratomas may secrete enzymes or hormones, such as vasopressin.<Reference refidx="22"/></Para></SummarySection><SummarySection id="_134"><Title>Malignant GCTs</Title><Para id="_259">GCTs contain frankly malignant tissues of germ cell origin and, rarely, tissues of somatic origin.  Isolated malignant elements may constitute a small fraction of a predominantly mature or immature teratoma.<Reference refidx="21"/><Reference refidx="23"/> </Para><Para id="_449">Malignant germ cell elements of children, adolescents, and young adults can be grouped broadly by location (refer to Tables 2 and 3).</Para><Table id="_317"><Title>Table 2.  Histology of Malignant Germ Cell Tumors in Young Children<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry>Malignant Germ Cell Elements</entry><entry>Location</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">E = extragonadal; O = ovarian; T = testicular.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Modified from Perlman et al.<Reference refidx="24"/></entry></Row></TFoot><TBody><Row><entry>Yolk sac tumor (endodermal sinus tumor)</entry><entry>E, O, T</entry></Row><Row><entry>Dysgerminoma (rare in young children)</entry><entry>O</entry></Row></TBody></TGroup></Table><Table id="_318"><Title>Table 3.  Histology of Malignant Germ Cell Tumors in Adolescents and Young Adults<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="50.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="50.00%"/><THead><Row><entry>Malignant Germ Cell Elements</entry><entry>Location</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">E = extragonadal; O = ovarian; T = testicular.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Modified from Perlman et al.<Reference refidx="24"/></entry></Row></TFoot><TBody><Row><entry>Seminoma</entry><entry>T</entry></Row><Row><entry>Dysgerminoma</entry><entry>O</entry></Row><Row><entry>Germinoma</entry><entry>E</entry></Row><Row><entry>Yolk sac tumor (endodermal sinus tumor)</entry><entry>E, O, T</entry></Row><Row><entry>Choriocarcinoma</entry><entry>E, O, T</entry></Row><Row><entry>Embryonal carcinoma</entry><entry>E, T</entry></Row><Row><entry>Mixed germ cell tumors</entry><entry>E, O, T</entry></Row></TBody></TGroup></Table><Para id="_263">Adolescent and young adult males present with more germinomas (testicular and mediastinal seminomas), and females present with more ovarian dysgerminomas.  </Para></SummarySection></SummarySection><SummarySection id="_204"><Title>Pediatric  GCT Biology</Title><Para id="_205">The following biologically distinct subtypes of GCTs are found in children and adolescents:</Para><ItemizedList id="_454" Style="bullet"><ListItem><SummaryRef href="CDR0000062854#_206" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Testicular GCTs</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_208" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Ovarian GCTs</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_210" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Extragonadal extracranial GCTs</SummaryRef>.</ListItem></ItemizedList><Para id="_455">It should be emphasized that very few pediatric GCT specimens have been analyzed to date.  Biologic distinctions between GCTs in children and GCTs in adults may not be absolute, and biologic factors have not been shown to predict risk.<Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/></Para><SummarySection id="_206"><Title>Testicular GCTs</Title><ItemizedList id="_207" Style="bullet" Compact="No"><ListItem><Strong>Children: </Strong>During early childhood, both testicular teratomas and malignant testicular GCTs are identified. The malignant tumors are commonly composed of pure yolk sac tumor (also known as endodermal
sinus tumor), are generally diploid or tetraploid, and often lack
the isochromosome of the short arm of chromosome 12 that characterizes testicular cancer in young adults.<Reference refidx="25"/><Reference refidx="28"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/> Deletions of chromosomes 1p, 4q, 
and 6q and gains of chromosomes 1q, 3, and 20q are reported as recurring chromosomal abnormalities for this group
of tumors.<Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/></ListItem><ListItem><Strong>Adolescents and young adults:</Strong> Testicular GCTs typically possess an isochromosome of the short arm of
chromosome 12 <Reference refidx="34"/><Reference refidx="35"/><Reference refidx="36"/><Reference refidx="37"/> and are aneuploid.<Reference refidx="28"/><Reference refidx="37"/>  Although adolescent testicular germ cell patients may be best treated at pediatric oncology centers, the treatment for adolescents older than 14 years follows the regimens used in adults. (Refer to the PDQ summary on <SummaryRef href="CDR0000062899" url="/types/testicular/hp/testicular-treatment-pdq">Testicular Cancer
Treatment</SummaryRef> for more information.)</ListItem></ItemizedList></SummarySection><SummarySection id="_208"><Title>Ovarian GCTs</Title><Para id="_209">Ovarian GCTs occur primarily in adolescent and young adult females. While most ovarian GCTs are benign mature teratomas, a heterogeneous group of malignant GCTs, including immature teratomas, dysgerminomas, yolk sac tumors, and mixed GCTs, do occur in females.    The malignant ovarian GCT commonly shows increased copies of the short arm of chromosome 12.<Reference refidx="38"/></Para><Para id="_456">Patients with pediatric ovarian GCTs have an excellent prognosis. One series of 66 patients monitored for more than 44 years reported recurrence rates of 4.5% and mortality rates of 3%.<Reference refidx="39"/> </Para><Para id="_457">(Refer to the PDQ summary on <SummaryRef href="CDR0000062935" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Ovarian Germ Cell Tumors Treatment</SummaryRef> for more information.)</Para></SummarySection><SummarySection id="_210"><Title>Extragonadal extracranial GCTs</Title><Para id="_458">Extragonadal extracranial GCTs occur outside of the brain and gonads.</Para><ItemizedList id="_211" Style="bullet" Compact="No"><ListItem><Strong>Children:</Strong> These tumors typically present at birth or during early childhood. Most of these tumors are benign teratomas occurring in the sacrococcygeal region, and thus are not included in Surveillance, Epidemiology, and End Results (SEER) data.<Reference refidx="40"/><Reference refidx="41"/> Malignant yolk sac tumor histology occurs in a minority of these tumors; however, they may have cytogenetic abnormalities similar to those observed for tumors occurring in the testes of young males.<Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="33"/></ListItem><ListItem><Strong>Older children, adolescents, and young adults:</Strong> The mediastinum is the most common primary site for extragonadal GCTs in older children and adolescents.<Reference refidx="15"/> Mediastinal GCTs in children  younger than 8 years share the same genetic gains and losses as sacrococcygeal and testicular tumors in young children.<Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/> The gain in chromosome 12p has been reported in mediastinal tumors in children aged 8 years and older.<Reference refidx="44"/><Reference refidx="45"/></ListItem></ItemizedList></SummarySection><Para id="_212">There are few data about the potential genetic or environmental factors
associated with childhood extragonadal extracranial GCTs.  Patients with
the following syndromes are at an increased risk of extragonadal extracranial GCTs:</Para><ItemizedList id="_459" Style="bullet" Compact="No"><ListItem>Klinefelter syndrome—increased risk of mediastinal GCTs.<Reference refidx="46"/><Reference refidx="47"/><Reference refidx="48"/></ListItem><ListItem>Swyer syndrome—increased risk of gonadoblastomas and germinomas.<Reference refidx="49"/><Reference refidx="50"/></ListItem><ListItem>Turner syndrome—increased risk of gonadoblastomas and germinomas.<Reference refidx="51"/><Reference refidx="52"/></ListItem></ItemizedList></SummarySection><SummarySection id="_450"><Title>Clinical Features</Title><Para id="_451">Childhood extracranial GCTs develop at diffuse sites that include the testicles, ovaries, mediastinum, retroperitoneum, sacrum, and coccyx. The clinical features at presentation are specific for each site.</Para><Para id="_636"><MediaLink ref="CDR0000770217" type="image/jpeg" alt="" language="en" thumb="Yes" id="_637"><Caption language="en">Figure 1.  Extracranial germ cell tumors form in parts of the body other than the brain.  This includes the testicles, ovaries, sacrum (lower part of the spine), coccyx (tailbone), mediastinum (area between the lungs), and retroperitoneum (the back wall of the abdomen).</Caption></MediaLink></Para></SummarySection><SummarySection id="_452"><Title>Diagnostic and Staging Evaluation</Title><Para id="_592">Diagnostic evaluation of GCTs includes imaging studies and measurement of tumor markers. In suspected cases, tumor markers can suggest the diagnosis before surgery and/or biopsy. This information can be used by the multidisciplinary team to make appropriate treatment choices.</Para><SummarySection id="_593"><Title>Tumor markers</Title><Para id="_453">Yolk sac tumors produce alpha-fetoprotein (AFP), while germinomas (seminomas and dysgerminomas), and especially choriocarcinomas, produce beta-human chorionic gonadotropin (beta-HCG), resulting in elevated serum levels of these substances. Most children with malignant GCTs will have a component of yolk sac tumor and have elevations of AFP levels,<Reference refidx="53"/> <Reference refidx="54"/> which are serially monitored during treatment to help assess response to therapy.<Reference refidx="21"/><Reference refidx="23"/><Reference refidx="53"/> Benign teratomas and immature teratomas may produce small elevations of AFP and beta-HCG.</Para><Para id="_594">During the first year of life, infants have a wide range of serum  AFP levels, which are not associated with the presence of a GCT. Normal ranges have been described but are based on limited data.<Reference refidx="55"/><Reference refidx="56"/> The serum half-life of AFP is 5 to 7 days, and the serum half-life of beta-HCG is 1 to 2 days. Even though the data are limited, tumor markers are measured with each cycle of chemotherapy for all pediatric patients with malignant GCTs. It should be recognized that after initial chemotherapy, tumor markers may show a transient  elevation.<Reference refidx="57"/></Para><Para id="_630">Although few pediatric data exist, adult studies have shown that an unsatisfactory decline of elevated tumor markers is a poor prognostic finding.<Reference refidx="58"/>  </Para></SummarySection><SummarySection id="_595"><Title>Imaging tests</Title><Para id="_596">Imaging tests may include the following:</Para><ItemizedList id="_597" Style="bullet"><ListItem>Computed tomography (CT) scan of the primary site and chest.</ListItem><ListItem>Magnetic resonance imaging (MRI) of the primary site.</ListItem><ListItem>Radionuclide bone scan or positron emission tomography scan (for postpubertal males).
</ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_631"><Title>Prognosis and Prognostic Factors</Title><Para id="_632">Prognosis and prognostic factors for extracranial GCTs depend on many circumstances, including the following:</Para><ItemizedList id="_633" Style="bullet"><ListItem>Histology (e.g., seminomatous vs. nonseminomatous).</ListItem><ListItem>Age (e.g., young children vs. adolescents).</ListItem><ListItem>Stage of disease.</ListItem><ListItem>Primary site of therapy.</ListItem><ListItem>Tumor's response to therapy.</ListItem></ItemizedList><Para id="_634">(Refer to the <SummaryRef href="CDR0000062854#_213" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Treatment of Mature and Immature Teratomas in Children</SummaryRef>, <SummaryRef href="CDR0000062854#_220" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Treatment of Malignant Gonadal GCTs in Children</SummaryRef>, and <SummaryRef href="CDR0000062854#_75" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Treatment of Malignant Extragonadal Extracranial GCTs in Children</SummaryRef> sections of this summary for more information about prognosis and prognostic factors for childhood extragonadal extracranial GCTs.)</Para></SummarySection><SummarySection id="_588"><Title>Follow-up After Treatment</Title><Para id="_598">There is little evidence to provide guidance on the follow-up care of children with extracranial GCTs. </Para><Para id="_599">The following tests and procedures may be performed at the physician's discretion when tumor markers are elevated at diagnosis:</Para><ItemizedList id="_600" Style="bullet" Compact="No"><ListItem>AFP and beta-HCG. Monitor AFP and beta-HCG levels monthly for 6 months  (period of highest risk) and then every 3 months, for a total of 2 years (3 years for sacrococcygeal teratoma).</ListItem><ListItem>Imaging tests. MRI/CT may be performed  at the completion of therapy. Further imaging intervals have not been defined.</ListItem></ItemizedList><Para id="_601">The following tests and procedures may be performed at the physician's discretion when tumor markers are normal at diagnosis:</Para><ItemizedList id="_602" Style="bullet"><ListItem>Imaging tests. Ultrasound or CT/MRI may be performed every 3 months for 2 years and then annually for 5 years for germinomas.</ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="20404250">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.</Citation><Citation idx="2" PMID="15173520">Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004.</Citation><Citation idx="3" PMID="24853691">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.</Citation><Citation idx="4" PMID="6343221" MedlineID="83211763">Dehner LP: Gonadal and extragonadal germ cell neoplasia of childhood. Hum Pathol 14 (6): 493-511, 1983.</Citation><Citation idx="5" PMID="18381640">McIntyre A, Gilbert D, Goddard N, et al.: Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. Genes Chromosomes Cancer 47 (7): 547-57, 2008.</Citation><Citation idx="6" PMID="8001010" MedlineID="95094135">Miller RW, Young JL Jr, Novakovic B: Childhood cancer. Cancer 75 (1 Suppl): 395-405, 1995.</Citation><Citation idx="7">Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649. <ExternalRef xref="http://seer.cancer.gov/publications/childhood/">Also available online.</ExternalRef> Last accessed May 26, 2015.</Citation><Citation idx="8" PMID="20597129">Poynter JN, Amatruda JF, Ross JA: Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer 116 (20): 4882-91, 2010.</Citation><Citation idx="9" PMID="15213888">Isaacs H Jr: Perinatal (fetal and neonatal) germ cell tumors. J Pediatr Surg 39 (7): 1003-13, 2004.</Citation><Citation idx="10" PMID="15613854">Heerema-McKenney A, Harrison MR, Bratton B, et al.: Congenital teratoma: a clinicopathologic study of 22 fetal and neonatal tumors. Am J Surg Pathol 29 (1): 29-38, 2005.</Citation><Citation idx="11" PMID="9533752">Hawkins EP: Germ cell tumors. Am J Clin Pathol 109 (4 Suppl 1): S82-8, 1998.</Citation><Citation idx="12" PMID="14752882">Schneider DT, Calaminus G, Koch S, et al.: Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer 42 (2): 169-75, 2004.</Citation><Citation idx="13" PMID="17719771">Horton Z, Schlatter M, Schultz S: Pediatric germ cell tumors. Surg Oncol 16 (3): 205-13, 2007.</Citation><Citation idx="14" PMID="9607423" MedlineID="98268439">Göbel U, Calaminus G, Engert J, et al.: Teratomas in infancy and childhood. Med Pediatr Oncol 31 (1): 8-15, 1998.</Citation><Citation idx="15" PMID="9988869">Rescorla FJ: Pediatric germ cell tumors. Semin Surg Oncol 16 (2): 144-58, 1999.</Citation><Citation idx="16" PMID="17080330">Harms D, Zahn S, Göbel U, et al.: Pathology and molecular biology of teratomas in childhood and adolescence. Klin Padiatr 218 (6): 296-302, 2006 Nov-Dec.</Citation><Citation idx="17" PMID="8979209">Tomlinson MW, Alaverdian AA, Alaverdian V: Testosterone-producing benign cystic teratoma with virilism. A case report. J Reprod Med 41 (12): 924-6, 1996.</Citation><Citation idx="18" PMID="1384444">Kallis P, Treasure T, Holmes SJ, et al.: Exocrine pancreatic function in mediastinal teratomata: an aid to preoperative diagnosis? Ann Thorac Surg 54 (4): 741-3, 1992.</Citation><Citation idx="19" PMID="1260722" MedlineID="76163013">Norris HJ, Zirkin HJ, Benson WL: Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 37 (5): 2359-72, 1976.</Citation><Citation idx="20" PMID="9737245" MedlineID="98407263">Heifetz SA, Cushing B, Giller R, et al.: Immature teratomas in children: pathologic considerations: a report from the combined Pediatric Oncology Group/Children's Cancer Group. Am J Surg Pathol 22 (9): 1115-24, 1998.</Citation><Citation idx="21" PMID="10561269" MedlineID="20029998">Marina NM, Cushing B, Giller R, et al.: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 17 (7): 2137-43, 1999.</Citation><Citation idx="22" PMID="8775270">Lam SK, Cheung LP: Inappropriate ADH secretion due to immature ovarian teratoma. Aust N Z J Obstet Gynaecol 36 (1): 104-5, 1996.</Citation><Citation idx="23" PMID="17080332">Göbel U, Calaminus G, Schneider DT, et al.: The malignant potential of teratomas in infancy and childhood: the MAKEI experiences in non-testicular teratoma and implications for a new protocol. Klin Padiatr 218 (6): 309-14, 2006 Nov-Dec.</Citation><Citation idx="24" PMID="10463297">Perlman EJ, Hawkins EP: Pediatric germ cell tumors: protocol update for pathologists. Pediatr Dev Pathol 1 (4): 328-35, 1998 Jul-Aug.</Citation><Citation idx="25" PMID="17285132">Palmer RD, Foster NA, Vowler SL, et al.: Malignant germ cell tumours of childhood: new associations of genomic imbalance. Br J Cancer 96 (4): 667-76, 2007.</Citation><Citation idx="26" PMID="18519683">Palmer RD, Barbosa-Morais NL, Gooding EL, et al.: Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res 68 (11): 4239-47, 2008.</Citation><Citation idx="27" PMID="22072546">Poynter JN, Hooten AJ, Frazier AL, et al.: Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors. Genes Chromosomes Cancer 51 (3): 266-71, 2012.</Citation><Citation idx="28" PMID="2536126" MedlineID="89095727">Oosterhuis JW, Castedo SM, de Jong B, et al.: Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance. Lab Invest 60 (1): 14-21, 1989.</Citation><Citation idx="29" PMID="7892165" MedlineID="95199223">Silver SA, Wiley JM, Perlman EJ: DNA ploidy analysis of pediatric germ cell tumors. Mod Pathol 7 (9): 951-6, 1994.</Citation><Citation idx="30" PMID="7971587" MedlineID="95061743">Perlman EJ, Cushing B, Hawkins E, et al.: Cytogenetic analysis of childhood endodermal sinus tumors: a Pediatric Oncology Group study. Pediatr Pathol 14 (4): 695-708, 1994 Jul-Aug.</Citation><Citation idx="31" PMID="11528555" MedlineID="21419551">Schneider DT, Schuster AE, Fritsch MK, et al.: Genetic analysis of childhood germ cell tumors with comparative genomic hybridization. Klin Padiatr 213 (4): 204-11, 2001 Jul-Aug.</Citation><Citation idx="32" PMID="10337997">Bussey KJ, Lawce HJ, Olson SB, et al.: Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences--a Children's Cancer Group study. Genes Chromosomes Cancer 25 (2): 134-46, 1999.</Citation><Citation idx="33" PMID="9162192" MedlineID="97013657">Perlman EJ, Valentine MB, Griffin CA, et al.: Deletion of 1p36 in childhood endodermal sinus tumors by two-color fluorescence in situ hybridization: a pediatric oncology group study. Genes Chromosomes Cancer 16 (1): 15-20, 1996.</Citation><Citation idx="34" PMID="7512366" MedlineID="94206868">Rodriguez E, Houldsworth J, Reuter VE, et al.: Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer 8 (4): 230-6, 1993.</Citation><Citation idx="35" PMID="8308927" MedlineID="94141962">Bosl GJ, Ilson DH, Rodriguez E, et al.: Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 86 (5): 349-55, 1994.</Citation><Citation idx="36" PMID="9632138" MedlineID="98293927">Mostert MC, Verkerk AJ, van de Pol M, et al.: Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 16 (20): 2617-27, 1998.</Citation><Citation idx="37" PMID="8527395" MedlineID="96108406">van Echten J, Oosterhuis JW, Looijenga LH, et al.: No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromosomes Cancer 14 (2): 133-44, 1995.</Citation><Citation idx="38" PMID="9679978" MedlineID="98343572">Riopel MA, Spellerberg A, Griffin CA, et al.: Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer Res 58 (14): 3105-10, 1998.</Citation><Citation idx="39" PMID="16206211">De Backer A, Madern GC, Oosterhuis JW, et al.: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer 46 (4): 459-64, 2006.</Citation><Citation idx="40" PMID="2156245" MedlineID="90192504">Malogolowkin MH, Mahour GH, Krailo M, et al.: Germ cell tumors in infancy and childhood: a 45-year experience. Pediatr Pathol 10 (1-2): 231-41, 1990.</Citation><Citation idx="41" PMID="6268666" MedlineID="82008224">Marsden HB, Birch JM, Swindell R: Germ cell tumours of childhood: a review of 137 cases. J Clin Pathol 34 (8): 879-83, 1981.</Citation><Citation idx="42" PMID="2790759" MedlineID="90002866">Dal Cin P, Drochmans A, Moerman P, et al.: Isochromosome 12p in mediastinal germ cell tumor. Cancer Genet Cytogenet 42 (2): 243-51, 1989.</Citation><Citation idx="43" PMID="8174074" MedlineID="94228462">Aly MS, Dal Cin P, Jiskoot P, et al.: Competitive in situ hybridization in a mediastinal germ cell tumor. Cancer Genet Cytogenet 73 (1): 53-6, 1994.</Citation><Citation idx="44" PMID="11921289" MedlineID="21917062">Schneider DT, Schuster AE, Fritsch MK, et al.: Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents. Genes Chromosomes Cancer 34 (1): 115-25, 2002.</Citation><Citation idx="45" PMID="17471115">McKenney JK, Heerema-McKenney A, Rouse RV: Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol 14 (2): 69-92, 2007.</Citation><Citation idx="46" PMID="2837589" MedlineID="88245450">Dexeus FH, Logothetis CJ, Chong C, et al.: Genetic abnormalities in men with germ cell tumors. J Urol 140 (1): 80-4, 1988.</Citation><Citation idx="47" PMID="3040921" MedlineID="87310573">Nichols CR, Heerema NA, Palmer C, et al.: Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5 (8): 1290-4, 1987.</Citation><Citation idx="48" PMID="3778123" MedlineID="87048001">Lachman MF, Kim K, Koo BC: Mediastinal teratoma associated with Klinefelter's syndrome. Arch Pathol Lab Med 110 (11): 1067-71, 1986.</Citation><Citation idx="49" PMID="9026505" MedlineID="97161638">Coutin AS, Hamy A, Fondevilla M, et al.: [Pure 46XY gonadal dysgenesis] J Gynecol Obstet Biol Reprod (Paris) 25 (8): 792-6, 1996.</Citation><Citation idx="50" PMID="3948114" MedlineID="86133098">Amice V, Amice J, Bercovici JP, et al.: Gonadal tumor and H-Y antigen in 46,XY pure gonadal dysgenesis. Cancer 57 (7): 1313-7, 1986.</Citation><Citation idx="51" PMID="7979900">Tanaka Y, Sasaki Y, Tachibana K, et al.: Gonadal mixed germ cell tumor combined with a large hemangiomatous lesion in a patient with Turner's syndrome and 45,X/46,X, +mar karyotype. Arch Pathol Lab Med 118 (11): 1135-8, 1994.</Citation><Citation idx="52" PMID="22629515">Kota SK, Gayatri K, Pani JP, et al.: Dysgerminoma in a female with turner syndrome and Y chromosome material: A case-based review of literature. Indian J Endocrinol Metab 16 (3): 436-40, 2012.</Citation><Citation idx="53" PMID="11078494" MedlineID="20530736">Mann JR, Raafat F, Robinson K, et al.: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (22): 3809-18, 2000.</Citation><Citation idx="54" PMID="1384951" MedlineID="93046025">Marina N, Fontanesi J, Kun L, et al.: Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 70 (10): 2568-75, 1992.</Citation><Citation idx="55" PMID="6163129">Wu JT, Book L, Sudar K: Serum alpha fetoprotein (AFP) levels in normal infants. Pediatr Res 15 (1): 50-2, 1981.</Citation><Citation idx="56" PMID="9592840">Blohm ME, Vesterling-Hörner D, Calaminus G, et al.: Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol 15 (2): 135-42, 1998 Mar-Apr.</Citation><Citation idx="57" PMID="6181870">Vogelzang NJ, Lange PH, Goldman A, et al.: Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42 (11): 4855-61, 1982.</Citation><Citation idx="58" PMID="17235042">Motzer RJ, Nichols CJ, Margolin KA, et al.: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25 (3): 247-56, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_18"><SectMetaData><SpecificDiagnosis ref="CDR0000043493">childhood extracranial germ cell tumor</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Childhood Extracranial GCTs</Title><Para id="_19">As with other childhood solid tumors, stage directly impacts the outcome of
patients with malignant germ cell tumors (GCTs).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  The most commonly used staging
systems in the United States are as follows:<Reference refidx="4"/></Para><ItemizedList id="_462" Style="bullet"><ListItem><SummaryRef href="CDR0000062854#_374" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Nonseminoma Testicular GCT Staging (Children's Oncology Group [COG])</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_376" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Ovarian GCT Staging (COG)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_378" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Ovarian GCT Staging (International Federation of Gynecology and Obstetrics [FIGO])</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_385" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Extragonadal Extracranial GCT Staging (COG)</SummaryRef>.</ListItem></ItemizedList><SummarySection id="_374"><Title>Nonseminoma Testicular GCT Staging From the  COG</Title><ItemizedList id="_375" Style="bullet" Compact="No"><ListItem><Strong>Stage I:</Strong> Limited to testis; complete resection by high inguinal orchiectomy or transscrotal resection with no tumor spillage. There must be no evidence of disease beyond the testis by radiologic scans or pathology. </ListItem><ListItem><Strong>Stage II:</Strong>  Transscrotal orchiectomy with spillage of tumor; microscopic disease in scrotum or high in spermatic cord (&gt;0.5 cm). Tumor markers increase or fail to normalize.</ListItem><ListItem><Strong>Stage III:</Strong>  Gross residual disease; retroperitoneal lymph node involvement (&gt;2 cm in boys younger than 10 years).</ListItem><ListItem><Strong>Stage IV:</Strong> Distant metastases, including liver, brain, bone, and lung.</ListItem></ItemizedList><Para id="_463">
  Retroperitoneal lymph node dissection has not been required in pediatric germ cell trials to stage disease in males younger than 15 years.  Data on adolescent males with testicular GCTs are limited.  Retroperitoneal lymph node dissection is used for both staging and treatment in adult testicular GCT trials.<Reference refidx="5"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062899" url="/types/testicular/hp/testicular-treatment-pdq">Testicular Cancer Treatment</SummaryRef> for more information about the staging of adult testicular GCTs.)</Para></SummarySection><SummarySection id="_376"><Title>Ovarian GCT Staging From the COG</Title><ItemizedList id="_377" Style="bullet" Compact="No"><ListItem><Strong>Stage I:</Strong>   Localized disease; completely resected without microscopic
disease in the resected margins or evidence of capsular rupture. Negative peritoneal cytology.</ListItem><ListItem><Strong>Stage II:</Strong>  Microscopic residual disease, capsular invasion, or microscopic lymph node involvement.</ListItem><ListItem><Strong>Stage III:</Strong> Gross residual disease, gross lymph node involvement (&gt;2 cm), or cytologic evidence of tumor cells in ascites.</ListItem><ListItem><Strong>Stage IV:</Strong>  Disseminated disease involving lungs, liver, brain, or bone.</ListItem></ItemizedList></SummarySection><SummarySection id="_378"><Title>Ovarian GCT Staging From the FIGO</Title><Para id="_379">Another ovarian GCT staging system used frequently by gynecologic oncologists is the
FIGO staging system, which
is based on adequate surgical staging at the time of diagnosis.<Reference refidx="6"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062935" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Ovarian Germ Cell Tumors Treatment</SummaryRef> for more information.)  This
system has also been used by some pediatric centers <Reference refidx="2"/> and is as follows:</Para><Table id="_617"><Title>Table 4.  FIGO Staging for Carcinoma of the Ovary<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="9.92%"/><ColSpec ColName="col2" ColNum="2" ColWidth="90.07%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Left"/></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Adapted from FIGO Committee on Gynecologic Oncology.<Reference refidx="7"/></entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>In order to evaluate the impact on prognosis of the different criteria for allotting cases to stage Ic or IIc, it is valuable to know whether rupture of the capsule was spontaneous, or caused by the surgeon; and whether the source of malignant cells detected was peritoneal washings or ascites.</entry></Row></TFoot><TBody><Row><entry>I</entry><entry>Growth limited to the ovaries.</entry></Row><Row><entry>Ia</entry><entry>Growth limited to one ovary; no ascites present containing malignant cells. No tumor on the external surface; capsule intact.</entry></Row><Row><entry>Ib</entry><entry>Growth limited to both ovaries; no ascites present containing malignant cells. No tumor on the external surfaces; capsules intact.</entry></Row><Row><entry>Ic<Superscript>b</Superscript></entry><entry>Tumor either stage Ia or Ib, but with tumor on surface of one or both ovaries, or with capsule ruptured, or with ascites present containing malignant cells, or with positive peritoneal washings.</entry></Row><Row><entry>II</entry><entry>Growth involving one or both ovaries with pelvic extension.</entry></Row><Row><entry>IIa</entry><entry>Extension and/or metastases to the uterus and/or tubes.</entry></Row><Row><entry>IIb</entry><entry>Extension to other pelvic tissues.</entry></Row><Row><entry>IIc<Superscript>b</Superscript></entry><entry>Tumor either stage IIa or IIb, but with tumor on surface of one or both ovaries, or with capsule(s) ruptured, or with ascites present containing malignant cells, or with positive peritoneal washings.</entry></Row><Row><entry>III</entry><entry>Tumor involving one or both ovaries with histologically confirmed peritoneal implants outside the pelvis and/or positive regional lymph nodes. Superficial liver metastases equals stage III. Tumor is limited to the true pelvis, but with histologically proven malignant extension to small bowel or omentum.</entry></Row><Row><entry>IIIa</entry><entry>Tumor grossly limited to the true pelvis, with negative nodes, but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces, or histologic proven extension to small bowel or mesentery.</entry></Row><Row><entry>IIIb</entry><entry>Tumor of one or both ovaries with histologically confirmed implants, peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 2 cm in diameter; nodes are negative.</entry></Row><Row><entry>IIIc</entry><entry>Peritoneal metastasis beyond the pelvis &gt;2 cm in diameter and/or positive regional lymph nodes.</entry></Row><Row><entry>IV</entry><entry>Growth involving one or both ovaries with distant metastases. If pleural effusion is present, there must be positive cytology to allot a case to stage IV. Parenchymal liver metastasis equals stage IV.</entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_385"><Title>Extragonadal Extracranial GCT Staging From the COG</Title><ItemizedList id="_386" Style="bullet" Compact="No"><ListItem><Strong>Stage I:</Strong> Localized disease; complete resection with no microscopic disease at margins or in regional lymph nodes. Tumor markers must normalize in appropriate half-life after resection. Complete coccygectomy for sacrococcygeal site.</ListItem><ListItem><Strong>Stage II:</Strong>  Microscopic residual disease, capsular invasion, and/or microscopic lymph node involvement. Tumor markers fail to normalize or increase.</ListItem><ListItem><Strong>Stage III:</Strong>  Gross residual disease and gross lymph node involvement (&gt;2 cm).</ListItem><ListItem><Strong>Stage IV:</Strong> Distant metastases, including liver, brain, bone, or lung.</ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="1717667" MedlineID="92014151">Ablin AR, Krailo MD, Ramsay NK, et al.: Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. J Clin Oncol 9 (10): 1782-92, 1991.</Citation><Citation idx="2" PMID="2467734" MedlineID="89195012">Mann JR, Pearson D, Barrett A, et al.: Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 63 (9): 1657-67, 1989.</Citation><Citation idx="3" PMID="1384951" MedlineID="93046025">Marina N, Fontanesi J, Kun L, et al.: Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 70 (10): 2568-75, 1992.</Citation><Citation idx="4" PMID="7284981" MedlineID="82025321">Brodeur GM, Howarth CB, Pratt CB, et al.: Malignant germ cell tumors in 57 children and adolescents. Cancer 48 (8): 1890-8, 1981.</Citation><Citation idx="5" PMID="17158533">de Wit R, Fizazi K: Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24 (35): 5482-92, 2006.</Citation><Citation idx="6" PMID="8155119" MedlineID="94019647">Cannistra SA: Cancer of the ovary. N Engl J Med 329 (21): 1550-9, 1993.</Citation><Citation idx="7" PMID="19322933">FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet 105 (1): 3-4, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_44"><SectMetaData><SpecificDiagnosis ref="CDR0000043493">childhood extracranial germ cell tumor</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment  Option Overview for Childhood Extracranial  GCTs</Title><Para id="_414">Childhood extracranial germ cell tumors (GCTs) are very heterogenous. The benefits and limitations of therapy are related to differences in histology. For example, pediatric GCTs, such as mature and immature teratomas, may not respond to chemotherapy.</Para><Para id="_464">Prognosis and appropriate treatment for extracranial GCTs depend on many factors, including the following:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> </Para><ItemizedList id="_465" Style="bullet"><ListItem>Histology (e.g., seminomatous vs. nonseminomatous).</ListItem><ListItem>Age (e.g., young children vs. adolescents).</ListItem><ListItem>Stage of disease.</ListItem><ListItem>Primary site of disease.</ListItem></ItemizedList><Para id="_466">To maximize the likelihood of long-term survival while minimizing the likelihood of treatment-related long-term sequelae (e.g., secondary leukemias, infertility, hearing loss, and renal dysfunction), children with extracranial malignant GCTs need to be cared for at pediatric cancer centers with experience treating these rare tumors. </Para><Para id="_467">On the basis of clinical factors, appropriate treatment for extracranial GCTs may involve one of the following: </Para><ItemizedList id="_468" Style="bullet"><ListItem>Surgical resection followed by careful monitoring for disease recurrence.</ListItem><ListItem>Initial surgical resection followed by platinum-based chemotherapy.</ListItem><ListItem>Diagnostic tumor biopsy and preoperative platinum-based chemotherapy followed by definitive tumor resection.<Reference refidx="5"/></ListItem></ItemizedList><Para id="_469">For patients with completely resected immature teratomas at any location (even those with malignant elements) and patients with localized, completely resected (stage I) gonadal tumors, additional therapy may not be necessary; however, close monitoring is important.<Reference refidx="6"/><Reference refidx="7"/> The watch-and-wait approach requires scheduled serial physical examination, tumor marker determination, and primary tumor imaging to ensure that a recurrent tumor is detected without delay. </Para><SummarySection id="_415"><Title>Surgery</Title><Para id="_416">Surgery is an essential component of treatment. Specific treatments will be discussed for each tumor type.</Para></SummarySection><SummarySection id="_470"><Title>Radiation Therapy</Title><Para id="_471">Testicular and mediastinal seminomas in males and ovarian dysgerminomas in females are sensitive to radiation, but radiation therapy is rarely recommended. With the advent of effective chemotherapy, it became possible for patients to avoid the toxic effects of radiation.</Para></SummarySection><SummarySection id="_418"><Title>Chemotherapy</Title><Para id="_137">Before effective chemotherapy became available, children with extracranial malignant GCTs had 3-year survival rates of 15% to 20% with surgery and radiation therapy,<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/> although young boys with localized testicular tumors did well with surgical resection.<Reference refidx="11"/><Reference refidx="12"/> Cisplatin-based chemotherapy has significantly improved outcomes for most children and adolescents with extracranial GCTs; 5-year survival rates now exceed 90%. </Para></SummarySection><Para id="_286">The standard chemotherapy regimen for both adults and children with malignant nonseminomatous GCTs includes cisplatin, etoposide, and bleomycin. Adult patients receive weekly bleomycin throughout treatment (bleomycin, etoposide, and cisplatin [BEP]). Pediatric patients do not  receive bleomycin during the weeks between cycles (cisplatin, etoposide, and bleomycin [PEB]). (Refer to <SummaryRef href="CDR0000062854#_156" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Table 5</SummaryRef> for adult BEP and pediatric PEB and JEB chemotherapy dosing schedules.)<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/>   The combination of carboplatin, etoposide, and bleomycin (JEB) underwent clinical investigation in the United Kingdom in children younger than 16 years  and was reported to have an event-free survival (EFS) by site and stage similar to that of PEB.<Reference refidx="3"/><Reference refidx="16"/> The use of JEB appears to be associated with fewer otologic toxic effects and renal toxic effects than does the use of PEB.<Reference refidx="3"/>   PEB and JEB have not been compared in a randomized pediatric GCT trial.</Para><Para id="_472">Adult studies have substituted standard-dose carboplatin for cisplatin in combination with etoposide alone and in combination with etoposide and low-dose bleomycin,<Reference refidx="17"/>  but the carboplatin regimens demonstrated inferior EFS and overall survival (OS) compared with cisplatin-containing therapy among patients with malignant GCTs. </Para><Para id="_473">Refer to Table  5 for adult BEP and pediatric PEB and JEB chemotherapy dosing schedules.</Para><Table id="_156"><Title>  Table 5.  Comparison of Adult BEP and Pediatric PEB and JEB Chemotherapy Dosing Schedules<Superscript>a</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="18.34%"/><ColSpec ColName="col2" ColNum="2" ColWidth="18.34%"/><ColSpec ColName="col3" ColNum="3" ColWidth="18.34%"/><ColSpec ColName="col4" ColNum="4" ColWidth="18.34%"/><ColSpec ColName="col5" ColNum="5" ColWidth="26.63%"/><THead><Row><entry>Regimen</entry><entry>Bleomycin</entry><entry>Etoposide</entry><entry>Cisplatin</entry><entry>Carboplatin</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">BEP = bleomycin, etoposide, and cisplatin; GFR = glomerular filtration rate; JEB = carboplatin, etoposide, and bleomycin; PEB = cisplatin, etoposide, and bleomycin.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Adult doses of PEB and JEB chemotherapy differ from pediatric doses. </entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>b</Superscript>The adult BEP regimen is provided here for comparison only; BEP is not used in the treatment of children.</entry></Row></TFoot><TBody><Row><entry>Adult BEP (every 21 days)<Superscript>b</Superscript> <Reference refidx="15"/><Reference refidx="18"/></entry><entry>30 units/m<Superscript>2</Superscript>, days 1, 8, 15</entry><entry>100 mg/m<Superscript>2</Superscript>, days 1–5</entry><entry>20 mg/m<Superscript>2</Superscript>, days 1–5</entry><entry/></Row><Row><entry>Pediatric PEB (every 21 days) <Reference refidx="1"/><Reference refidx="2"/></entry><entry>15 units/m², day 1</entry><entry>100 mg/m², days 1–5</entry><entry>20 mg/m², days 1–5</entry><entry/></Row><Row><entry>Pediatric JEB (every 21–28 days) <Reference refidx="3"/></entry><entry>15 units/m², day  3 </entry><entry>120 mg/m², days 1–3</entry><entry/><entry>600 mg/m² or  GFR-based dosing,  day 2</entry></Row></TBody></TGroup></Table><Para id="_287">The approach to the management of extracranial GCTs has been derived from the results of several intergroup studies conducted by the Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="6"/> These studies explored the use of PEB for the treatment of localized gonadal GCT <Reference refidx="1"/> and the benefit of increasing the dose of cisplatin (high-dose PEB [HD-PEB]: a cisplatin concentration of 200 mg/m<Superscript>2</Superscript> vs. PEB: a cisplatin concentration of 100 mg/m<Superscript>2</Superscript>) 
in a randomized manner in patients with 
extragonadal and advanced gonadal GCTs.<Reference refidx="2"/> The intensification of cisplatin in the HD-PEB regimen provided some improvement in EFS but no difference in OS; however, the use of HD-PEB was associated with a significantly higher incidence and severity of otologic toxic effects and renal toxic effects. In a subsequent study, amifostine was not effective in preventing hearing loss in patients who received HD-PEB.<Reference refidx="19"/> </Para><Para id="_139">  Table   6 provides an
overview of standard treatment options for children with extracranial GCTs.  Specific details of treatment by primary site and clinical condition are described in subsequent sections.
</Para><Table id="_587"><Title>Table 6.  Standard Treatment Options for Childhood Extracranial Germ Cell Tumors (GCTs)</Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="2.89%"/><ColSpec ColName="col02" ColNum="2" ColWidth="3.21%"/><ColSpec ColName="col3" ColNum="3" ColWidth="45.49%"/><ColSpec ColName="col2" ColNum="4" ColWidth="48.39%"/><THead><Row><entry NameEnd="col3" NameSt="col1">Histology</entry><entry>Standard Treatment Options</entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">JEB = carboplatin, etoposide, and bleomycin; PEB = cisplatin, etoposide, and bleomycin.</entry></Row></TFoot><TBody><Row><entry NameEnd="col3" NameSt="col1">Mature teratoma (nonsacrococcygeal)</entry><entry><SummaryRef href="CDR0000062854#_474" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation</SummaryRef></entry></Row><Row><entry MoreRows="1" NameEnd="col3" NameSt="col1">Immature teratoma (nonsacrococcygeal)</entry><entry><SummaryRef href="CDR0000062854#_604" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef> </entry></Row><Row><entry><SummaryRef href="CDR0000062854#_609" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (stages II–IV)</SummaryRef> (refer to the <SummaryRef href="CDR0000062854#_70" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Childhood Malignant Ovarian GCTs</SummaryRef> section of this summary for specific information about the treatment of ovarian immature teratoma)</entry></Row><Row><entry NameEnd="col3" NameSt="col1">Mature and immature teratomas (sacrococcygeal)</entry><entry><SummaryRef href="CDR0000062854#_310" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation</SummaryRef></entry></Row><Row><entry NameEnd="col3" NameSt="col1">Malignant gonadal GCTs in children:</entry><entry/></Row><Row><entry/><entry NameEnd="col3" NameSt="col02">Childhood malignant testicular GCTs:</entry><entry/></Row><Row><entry MoreRows="1"/><entry MoreRows="1"/><entry MoreRows="1">Malignant testicular GCTs in prepubertal males</entry><entry><SummaryRef href="CDR0000062854#_532" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062854#_535" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (PEB) (stages II–IV)</SummaryRef></entry></Row><Row><entry/><entry/><entry>Malignant testicular GCTs in postpubertal males</entry><entry>Refer to the PDQ summary on <SummaryRef href="CDR0000062899" url="/types/testicular/hp/testicular-treatment-pdq">Testicular Cancer Treatment</SummaryRef> for more information.</entry></Row><Row><entry/><entry NameEnd="col3" NameSt="col02">Childhood malignant ovarian GCTs:</entry><entry/></Row><Row><entry MoreRows="1"/><entry MoreRows="1"/><entry MoreRows="1">Dysgerminomas of the ovary</entry><entry><SummaryRef href="CDR0000062854#_538" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062854#_541" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (PEB) (stages II–IV)</SummaryRef></entry></Row><Row><entry MoreRows="2"/><entry MoreRows="2"/><entry MoreRows="2">Malignant nongerminomatous ovarian GCTs (yolk sac and mixed GCTs)</entry><entry><SummaryRef href="CDR0000062854#_545" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef> (refer to the <SummaryRef href="CDR0000062854#_70" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Childhood Malignant Ovarian GCTs</SummaryRef> section of this summary for specific information about the treatment of ovarian immature teratoma)</entry></Row><Row><entry><SummaryRef href="CDR0000062854#_549" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (PEB) (stage I and stages II–IV)</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062854#_552" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Biopsy followed by chemotherapy (PEB) and surgery (initially unresectable tumors)</SummaryRef></entry></Row><Row><entry MoreRows="1" NameEnd="col3" NameSt="col1">Malignant extragonadal extracranial GCTs in children</entry><entry><SummaryRef href="CDR0000062854#_555" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (PEB)</SummaryRef></entry></Row><Row><entry><SummaryRef href="CDR0000062854#_555" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Biopsy followed by chemotherapy (PEB) and possibly surgery</SummaryRef></entry></Row><Row><entry NameEnd="col3" NameSt="col1">Recurrent malignant GCTs in children </entry><entry>Refer to the <SummaryRef href="CDR0000062854#_79" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Treatment of Recurrent Malignant  GCTs in Children</SummaryRef> section of this summary for more information.</entry></Row></TBody></TGroup></Table><SummarySection id="_397"><Title>GCT With Non-GCT Elements</Title><Para id="_398">The treatment of GCTs with other non-GCT elements is complex, and few data exist to direct treatment.  In adolescents, central primitive neuroectodermal tumors and sarcomas have been found in teratomas.<Reference refidx="20"/><Reference refidx="21"/> The Italian Pediatric Germ Cell Tumor group identified 14 patients with malignant somatic tumors, such as neuroblastoma and rhabdomyosarcoma, embedded in teratomas (&lt;2% of extracranial GCTs).<Reference refidx="22"/> The optimal treatment strategy for GCTs with non-GCT elements  has not been determined, and separate treatments for both malignant GCTs and non-GCT elements may be required.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15337806">Rogers PC, Olson TA, Cullen JW, et al.: Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22 (17): 3563-9, 2004.</Citation><Citation idx="2" PMID="15226336">Cushing B, Giller R, Cullen JW, et al.: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22 (13): 2691-700, 2004.</Citation><Citation idx="3" PMID="11078494" MedlineID="20530736">Mann JR, Raafat F, Robinson K, et al.: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (22): 3809-18, 2000.</Citation><Citation idx="4" PMID="11283126">Göbel U, Schneider DT, Calaminus G, et al.: Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 19 (7): 1943-50, 2001.</Citation><Citation idx="5" PMID="9988869">Rescorla FJ: Pediatric germ cell tumors. Semin Surg Oncol 16 (2): 144-58, 1999.</Citation><Citation idx="6" PMID="10561269" MedlineID="20029998">Marina NM, Cushing B, Giller R, et al.: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 17 (7): 2137-43, 1999.</Citation><Citation idx="7" PMID="12632342" MedlineID="22519191">Schlatter M, Rescorla F, Giller R, et al.: Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg 38 (3): 319-24; discussion 319-24, 2003.</Citation><Citation idx="8" PMID="63318" MedlineID="77066746">Kurman RJ, Norris HJ: Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 38 (6): 2404-19, 1976.</Citation><Citation idx="9" PMID="5458260" MedlineID="70289400">Chretien PB, Milam JD, Foote FW, et al.: Embryonal adenocarcinomas (a type of malignant teratoma) of the sacrococcygeal region. Clinical and pathologic aspects of 21 cases. Cancer 26 (3): 522-35, 1970.</Citation><Citation idx="10" PMID="2425069" MedlineID="86253649">Billmire DF, Grosfeld JL: Teratomas in childhood: analysis of 142 cases. J Pediatr Surg 21 (6): 548-51, 1986.</Citation><Citation idx="11" PMID="3022907" MedlineID="87051241">Hawkins EP, Finegold MJ, Hawkins HK, et al.: Nongerminomatous malignant germ cell tumors in children. A review of 89 cases from the Pediatric Oncology Group, 1971-1984. Cancer 58 (12): 2579-84, 1986.</Citation><Citation idx="12" PMID="1384951" MedlineID="93046025">Marina N, Fontanesi J, Kun L, et al.: Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 70 (10): 2568-75, 1992.</Citation><Citation idx="13" PMID="11250991" MedlineID="21150310">de Wit R, Roberts JT, Wilkinson PM, et al.: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19 (6): 1629-40, 2001.</Citation><Citation idx="14" PMID="1690272" MedlineID="90188473">Gershenson DM, Morris M, Cangir A, et al.: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8 (4): 715-20, 1990.</Citation><Citation idx="15" PMID="2437455" MedlineID="87201806">Williams SD, Birch R, Einhorn LH, et al.: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316 (23): 1435-40, 1987.</Citation><Citation idx="16" PMID="12210444" MedlineID="22199335">Stern JW, Bunin N: Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 39 (3): 163-7, 2002.</Citation><Citation idx="17" PMID="9164194" MedlineID="97306979">Horwich A, Sleijfer DT, Fosså SD, et al.: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 15 (5): 1844-52, 1997.</Citation><Citation idx="18" PMID="2465391" MedlineID="89140928">Einhorn LH, Williams SD, Loehrer PJ, et al.: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 7 (3): 387-91, 1989.</Citation><Citation idx="19" PMID="15999362">Marina N, Chang KW, Malogolowkin M, et al.: Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 104 (4): 841-7, 2005.</Citation><Citation idx="20" PMID="20231305">Ehrlich Y, Beck SD, Ulbright TM, et al.: Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. Ann Oncol 21 (9): 1846-50, 2010.</Citation><Citation idx="21" PMID="24952240">Rice KR, Magers MJ, Beck SD, et al.: Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes. J Urol 192 (5): 1403-9, 2014.</Citation><Citation idx="22" PMID="20049928">Terenziani M, D'Angelo P, Bisogno G, et al.: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer 54 (4): 532-7, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_213"><SectMetaData><SpecificDiagnosis ref="CDR0000043494">childhood teratoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Mature and Immature Teratomas in Children</Title><Para id="_387">Mature and immature teratomas arise primarily in the sacrococcygeal region of neonates and young children and in the ovaries of pubescent girls. Less commonly, these tumors are found in the testicular region of boys younger than 4 years, the mediastinum of adolescents, and other sites.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> The primary treatment for teratomas is surgery and depends on whether the tumor forms in a nonsacrococcygeal or sacrococcygeal site. Surgical options for sacrococcygeal teratomas are complex. The number of pediatric patients with postoperative residual mature or immature teratomas is very small.</Para><SummarySection id="_217"><Title>Mature Teratomas (Nonsacrococcygeal Sites)</Title><SummarySection id="_474"><Title>Standard treatment options for mature teratomas (nonsacrococcygeal sites)</Title><Para id="_475">Standard treatment options for mature teratomas in a nonsacrococcygeal site include the following:</Para><OrderedList id="_496" Style="Arabic"><ListItem>Surgery and observation.</ListItem></OrderedList><Para id="_218">Children with mature teratomas, including mature teratomas of the mediastinum, can be treated with surgery and observation, with an excellent prognosis.<Reference refidx="1"/><Reference refidx="4"/> In a review of 153 children with nontesticular mature teratoma, the 6-year relapse-free survival was 96% for completely resected disease and 55% for incompletely resected disease.<Reference refidx="2"/> </Para><Para id="_477">Head and neck germ cell tumors (GCTs) in neonates should be cared for by a multidisciplinary team. Although most head and neck GCTs are benign, they  present significant challenges to surgeons. Some tumors develop malignant elements, which may change the treatment strategy.<Reference refidx="5"/></Para><Para id="_478">Mature teratomas in the prepubertal testis are relatively common benign lesions and may be amenable to testis-sparing surgery.<Reference refidx="6"/>  
 </Para></SummarySection></SummarySection><SummarySection id="_479"><Title>Immature Teratomas (Nonsacrococcygeal Sites)</Title><SummarySection id="_480"><Title>Standard treatment options for immature teratomas (nonsacrococcygeal sites)</Title><Para id="_481">Standard treatment options for immature teratomas in a nonsacrococcygeal site include the following:</Para><OrderedList id="_497" Style="Arabic"><ListItem><SummaryRef href="CDR0000062854#_604" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_609" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (stages II through IV)</SummaryRef>.</ListItem></OrderedList><Para id="_603">The treatment options for immature teratomas at a nonsacrococcygeal site differ by stage of disease.</Para><SummarySection id="_604"><Title>Stage I</Title><Para id="_605">Infants and young children  with immature teratomas have an excellent prognosis if the tumor can be completely resected.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/> For these patients, the current standard of treatment is surgery and observation.</Para><Para id="_606">Evidence (surgery and observation for stage I disease):</Para><OrderedList id="_607" Style="Arabic" Compact="No"><ListItem>The benefit of adjuvant chemotherapy for children was investigated in a study by the Pediatric Oncology Group and Children's Cancer Group. Surgical resection followed by careful observation was used to treat patients with immature teratomas.<Reference refidx="10"/><ItemizedList id="_608" Style="bullet" Compact="No"><ListItem>Surgery alone was curative for most children and adolescents with resected ovarian immature teratomas of any grade, even when elevated levels of serum alpha-fetoprotein (AFP) or microscopic foci of yolk sac tumor were present.</ListItem><ListItem>The study demonstrated a 3-year event-free survival of 97.8% for patients with ovarian tumors, 100% for patients with testicular tumors, and 80% for patients with extragonadal tumors.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_609"><Title>Stages II through IV</Title><Para id="_610">There is significant debate on the responsiveness of immature teratomas to  chemotherapy. In adults, and perhaps adolescents, immature teratomas (primarily ovarian) reportedly have an aggressive clinical behavior <Reference refidx="11"/> requiring surgery and chemotherapy. The decision to use chemotherapy is based on the tumor stage (II through IV) and grade. In a pediatric report from the United Kingdom, immature teratomas did not respond to chemotherapy.<Reference refidx="12"/> This study did not include patients older than 15 years. Further studies on the treatment of ovarian immature teratomas with chemotherapy are needed. (Refer to the PDQ summary on <SummaryRef href="CDR0000062935" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Ovarian Germ Cell Tumors Treatment</SummaryRef> for more information about the treatment of ovarian immature teratomas in postpubertal females.)</Para></SummarySection></SummarySection></SummarySection><SummarySection id="_214"><Title>Mature and Immature Teratomas  (Sacrococcygeal Site)</Title><Para id="_215">The sacrococcygeal region is the primary tumor site for most benign and malignant GCTs diagnosed in neonates, infants, and children younger than 4 years.  These tumors occur more often in girls than in boys; ratios of 3:1 to 4:1 have been reported.<Reference refidx="13"/> </Para><Para id="_488">Sacrococcygeal tumors present in the following two clinical patterns related to the child’s age, tumor location, and likelihood of tumor malignancy:<Reference refidx="1"/></Para><ItemizedList id="_489" Style="bullet" Compact="No"><ListItem>Neonates: Neonatal tumors present at birth protruding from the sacral site and are usually mature or immature teratomas.</ListItem><ListItem>Infants and young children: In infants and young children, the tumor presents as a palpable mass in the sacro-pelvic region, compressing the bladder or rectum.  These pelvic tumors are more likely to be malignant.  An early survey found that the rate of tumor malignancy was 48% for girls and 67% for boys older than 2 months at the time of sacrococcygeal tumor diagnosis, compared with a malignant tumor incidence of 7% for girls and 10% for boys younger than 2 months at the time of diagnosis.<Reference refidx="14"/>  The pelvic site of the primary tumor has been reported to be an adverse prognostic factor, perhaps as a result of delayed diagnosis because it was unappreciated at birth or because of incomplete resection at the time of original surgery.<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/></ListItem></ItemizedList><SummarySection id="_310"><Title>Standard treatment options for mature and immature teratomas (sacrococcygeal sites)</Title><Para id="_490">Standard treatment options for mature and immature teratomas in a sacrococcygeal site include the following:</Para><OrderedList id="_491" Style="Arabic"><ListItem>Surgery and observation.</ListItem></OrderedList><Para id="_216">Surgery is an essential component of treatment. Complete resection of the coccyx is vital to minimize the likelihood of tumor recurrence;<Reference refidx="2"/>    however, one study reported that 11 of 12 patients with microscopic residual benign immature teratomas had no recurrence.<Reference refidx="18"/>  </Para><Para id="_635">After successful resection, neonates diagnosed with benign mature and immature teratomas are closely observed with follow-up exams and serial serum AFP determinations for several years to ensure that the expected physiological normalization of AFP levels occurs and to facilitate early detection of tumor relapse.<Reference refidx="19"/>  A significant rate of recurrence among these benign tumors, ranging from 10% to 21%, has been reported by several groups, with most relapses occurring within 3 years of resection.<Reference refidx="9"/><Reference refidx="13"/><Reference refidx="19"/>   <Reference refidx="20"/></Para><Para id="_492">While there is no standard follow-up schedule, tumor markers are measured frequently for 3 years in all children. Recurrent tumors will be malignant in 43% to 50% of cases, and yolk sac tumor is the most common histology. With early detection, recurrent malignant GCTs can be treated successfully with surgery and chemotherapy (overall survival, 92%).<Reference refidx="21"/>  Long-term survivors are monitored for complications of extensive surgery, which include constipation, fecal and urinary incontinence, and psychologically unacceptable cosmetic scars.<Reference refidx="22"/></Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_213_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_213_20">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43494&amp;tt=1&amp;format=2&amp;cn=1">childhood teratoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_213_21">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="9988869">Rescorla FJ: Pediatric germ cell tumors. Semin Surg Oncol 16 (2): 144-58, 1999.</Citation><Citation idx="2" PMID="9607423" MedlineID="98268439">Göbel U, Calaminus G, Engert J, et al.: Teratomas in infancy and childhood. Med Pediatr Oncol 31 (1): 8-15, 1998.</Citation><Citation idx="3" PMID="9291812" MedlineID="97437279">Pinkerton CR: Malignant germ cell tumours in childhood. Eur J Cancer 33 (6): 895-901; discussion 901-2, 1997.</Citation><Citation idx="4" PMID="10673525" MedlineID="20139488">Schneider DT, Calaminus G, Reinhard H, et al.: Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. J Clin Oncol 18 (4): 832-9, 2000.</Citation><Citation idx="5" PMID="18937314">Bernbeck B, Schneider DT, Bernbeck B, et al.: Germ cell tumors of the head and neck: report from the MAKEI Study Group. Pediatr Blood Cancer 52 (2): 223-6, 2009.</Citation><Citation idx="6" PMID="14634440">Metcalfe PD, Farivar-Mohseni H, Farhat W, et al.: Pediatric testicular tumors: contemporary incidence and efficacy of testicular preserving surgery. J Urol 170 (6 Pt 1): 2412-5; discussion 2415-6, 2003.</Citation><Citation idx="7" PMID="6165455" MedlineID="81209829">Valdiserri RO, Yunis EJ: Sacrococcygeal teratomas: a review of 68 cases. Cancer 48 (1): 217-21, 1981.</Citation><Citation idx="8" PMID="7053836" MedlineID="82093113">Carter D, Bibro MC, Touloukian RJ: Benign clinical behavior of immature mediastinal teratoma in infancy and childhood: report of two cases and review of the literature. Cancer 49 (2): 398-402, 1982.</Citation><Citation idx="9" PMID="580884" MedlineID="78209932">Gonzalez-Crussi F, Winkler RF, Mirkin DL: Sacrococcygeal teratomas in infants and children: relationship of histology and prognosis in 40 cases. Arch Pathol Lab Med 102 (8): 420-5, 1978.</Citation><Citation idx="10" PMID="10561269" MedlineID="20029998">Marina NM, Cushing B, Giller R, et al.: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 17 (7): 2137-43, 1999.</Citation><Citation idx="11" PMID="1260722" MedlineID="76163013">Norris HJ, Zirkin HJ, Benson WL: Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 37 (5): 2359-72, 1976.</Citation><Citation idx="12" PMID="18541896">Mann JR, Gray ES, Thornton C, et al.: Mature and immature extracranial teratomas in children: the UK Children's Cancer Study Group Experience. J Clin Oncol 26 (21): 3590-7, 2008.</Citation><Citation idx="13" PMID="9498381">Rescorla FJ, Sawin RS, Coran AG, et al.: Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 33 (2): 171-6, 1998.</Citation><Citation idx="14" PMID="4843993">Altman RP, Randolph JG, Lilly JR: Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 9 (3): 389-98, 1974.</Citation><Citation idx="15" PMID="1717667" MedlineID="92014151">Ablin AR, Krailo MD, Ramsay NK, et al.: Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group. J Clin Oncol 9 (10): 1782-92, 1991.</Citation><Citation idx="16" PMID="1384951" MedlineID="93046025">Marina N, Fontanesi J, Kun L, et al.: Treatment of childhood germ cell tumors. Review of the St. Jude experience from 1979 to 1988. Cancer 70 (10): 2568-75, 1992.</Citation><Citation idx="17" PMID="10561181" MedlineID="20029910">Baranzelli MC, Kramar A, Bouffet E, et al.: Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 17 (4): 1212, 1999.</Citation><Citation idx="18" PMID="16410129">De Backer A, Madern GC, Hakvoort-Cammel FG, et al.: Study of the factors associated with recurrence in children with sacrococcygeal teratoma. J Pediatr Surg 41 (1): 173-81; discussion 173-81, 2006.</Citation><Citation idx="19" PMID="12721723">Huddart SN, Mann JR, Robinson K, et al.: Sacrococcygeal teratomas: the UK Children's Cancer Study Group's experience. I. Neonatal. Pediatr Surg Int 19 (1-2): 47-51, 2003.</Citation><Citation idx="20" PMID="16952583">Gabra HO, Jesudason EC, McDowell HP, et al.: Sacrococcygeal teratoma--a 25-year experience in a UK regional center. J Pediatr Surg 41 (9): 1513-6, 2006.</Citation><Citation idx="21" PMID="22459912">De Corti F, Sarnacki S, Patte C, et al.: Prognosis of malignant sacrococcygeal germ cell tumours according to their natural history and surgical management. Surg Oncol 21 (2): e31-7, 2012.</Citation><Citation idx="22" PMID="17560233">Derikx JP, De Backer A, van de Schoot L, et al.: Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands. J Pediatr Surg 42 (6): 1122-6, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_220"><Title> Treatment of Malignant Gonadal  GCTs in Children</Title><SummarySection id="_60"><SectMetaData><SpecificDiagnosis ref="CDR0000043495">childhood malignant testicular germ cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Childhood Malignant Testicular GCTs</Title><SummarySection id="_61"><Title>Malignant testicular GCTs in prepubertal males</Title><Para id="_62">Testicular germ cell tumors (GCTs) in children occur almost exclusively in boys
younger than 4 years.<Reference refidx="1"/><Reference refidx="2"/> The initial surgical approach to evaluate a testicular mass in a young boy is important  because a transscrotal biopsy can risk inguinal node metastasis.<Reference refidx="3"/><Reference refidx="4"/> Radical inguinal orchiectomy with initial high
ligation of the spermatic cord is the procedure of choice.<Reference refidx="5"/> 
</Para><Para id="_493">Computed tomography or magnetic resonance imaging evaluation, with the additional information provided by elevated tumor markers, appears adequate for staging. Retroperitoneal
dissection of lymph nodes is not beneficial in the staging of testicular GCTs in young boys.<Reference refidx="3"/><Reference refidx="4"/> Therefore,  there is no reason to risk the potential morbidity (e.g., impotence and retrograde ejaculation) associated with lymph node dissection.<Reference refidx="6"/><Reference refidx="7"/></Para><Para id="_499">The role of surgery at diagnosis for GCTs is age- and site-dependent and must be individualized. All malignant testicular GCTs should be resected. Primary resection of other areas of disease may be appropriate when feasible, without undue risk of damage to adjacent structures; otherwise, an appropriate strategy is resection of the testis for diagnosis followed by subsequent excision in selected patients who have residual masses after undergoing chemotherapy.</Para><SummarySection id="_289"><Title>Standard treatment options for malignant GCTs in prepubertal males</Title><Para id="_494">Standard treatment options for malignant GCTs in prepubertal males (younger than 15 years)  include the following:</Para><OrderedList id="_495" Style="Arabic"><ListItem><SummaryRef href="CDR0000062854#_532" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_535" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (stages II through IV)</SummaryRef>.</ListItem></OrderedList><Para id="_500">The treatment options for malignant GCTs in prepubertal males differ by stage of disease.</Para><SummarySection id="_532"><Title>Stage I</Title><Para id="_533">Surgery and close follow-up observation are indicated to document that a normalization of the tumor markers occurs after resection.<Reference refidx="3"/><Reference refidx="8"/></Para><Para id="_501">Evidence (surgery and observation for stage I disease):</Para><OrderedList id="_534" Style="Arabic" Compact="No"><ListItem>A  Children’s Cancer Group (CCG)/Pediatric Oncology Group (POG) clinical
trial evaluated surgery followed by observation for boys aged 10 years or younger with stage I
testicular tumors.<Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_503" Style="bullet" Compact="No"><ListItem>This  treatment strategy resulted in a 6-year event-free survival (EFS) of 82%. </ListItem><ListItem>Boys who developed recurrent disease received salvage therapy with four cycles of standard-dose cisplatin, etoposide, and bleomycin (PEB), with a 6-year survival of 100%.</ListItem></ItemizedList></ListItem><ListItem>A German study (MAHO 98) of 128 boys younger than 10 years with testis GCTs, mostly stage I, also evaluated surgery followed by observation.<Reference refidx="9"/>[<LOERef href="CDR0000335144">Level of evidence: 3iiA</LOERef>]<ItemizedList id="_619" Style="bullet" Compact="No"><ListItem>Investigators reported  results similar to the CCG/POG study with the same watch-and-wait strategy. Very few patients relapsed, and 100% of patients survived.</ListItem></ItemizedList></ListItem></OrderedList></SummarySection><SummarySection id="_535"><Title>Stages II through IV</Title><Para id="_536">Surgery and chemotherapy with four cycles of standard PEB is a common treatment regimen. Patients treated with this regimen have an overall survival (OS) outcome greater than 90%, suggesting that a reduction in therapy could be considered.<Reference refidx="10"/><Reference refidx="11"/></Para><Para id="_537">Surgery and treatment with four to six cycles of carboplatin, etoposide, and bleomycin (JEB) is an alternative treatment regimen.<Reference refidx="8"/></Para><Para id="_504">Evidence (surgery and chemotherapy for stages II–IV disease):</Para><OrderedList id="_505" Style="Arabic" Compact="No"><ListItem>A  CCG/POG clinical
trial evaluated boys younger than 10 years with stage II tumors who were treated with four cycles of PEB after diagnosis.<Reference refidx="10"/> <ItemizedList id="_506" Style="bullet" Compact="No"><ListItem>The 6-year EFS and OS rates were 100%.</ListItem></ItemizedList></ListItem><ListItem>In the same CCG/POG clinical trial, boys and adolescents (age not limited to 10 years or younger) with stage III and stage IV testicular tumors were treated with surgical resection followed by four cycles of standard-dose PEB or high-dose PEB (HD-PEB) therapy.<Reference refidx="11"/>  <ItemizedList id="_507" Style="bullet" Compact="No"><ListItem>The 6-year survival outcome for males younger than 15 years with stage III and   stage IV tumors was 100%.</ListItem><ListItem>The 6-year  EFS for males younger than 15 years was 100% for stage III tumors and 94% for stage IV tumors.</ListItem><ListItem>The use of HD-PEB therapy did not improve the outcome for these boys but did cause increased incidence of otologic toxic effects.  </ListItem></ItemizedList></ListItem><ListItem>Excellent outcomes for boys with testicular GCTs using surgery and observation for stage I tumors and JEB and other cisplatin-containing chemotherapy regimens for stage II, stage III, and stage IV tumors have also been reported by European investigators.<Reference refidx="6"/><Reference refidx="8"/>  </ListItem></OrderedList></SummarySection></SummarySection></SummarySection><SummarySection id="_66"><Title>Malignant testicular GCTs in postpubertal males</Title><Para id="_68">   The
treatment options described above for young boys   may not be strictly applicable
to  adolescent males (aged 15 years and older).
In particular, the use of retroperitoneal lymph node dissection  may play a crucial role  in the evaluation of early-stage testicular GCT <Reference refidx="12"/> and for residual disease after chemotherapy for the treatment of metastatic GCT.<Reference refidx="13"/><Reference refidx="14"/>  </Para><Para id="_509">In this age group, the presence of a sarcomatous component in the primary testis GCT does not alter the prognosis; however, if a sarcomatous component  is found in a metastatic lesion, survival is likely to be compromised.<Reference refidx="15"/></Para><SummarySection id="_510"><Title>Standard treatment options for malignant testicular GCTs in postpubertal males</Title><Para id="_67">Refer to the PDQ summary on <SummaryRef href="CDR0000062899" url="/types/testicular/hp/testicular-treatment-pdq">Testicular Cancer Treatment</SummaryRef> for more information about the treatment of malignant testicular GCTs in postpubertal males.</Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_60_sid_2"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_60_20">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43495&amp;tt=1&amp;format=2&amp;cn=1">childhood malignant testicular germ cell tumor</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_60_21">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><SummarySection id="_70"><SectMetaData><SpecificDiagnosis ref="CDR0000043496">childhood malignant ovarian germ cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Childhood Malignant Ovarian GCTs</Title><Para id="_144">Most ovarian neoplasms in children and adolescents are of germ cell origin.<Reference refidx="1"/>  Ovarian GCTs are very rare in young girls, but the incidence begins to increase in children aged approximately  8 or 9 years and continues to rise throughout adulthood.<Reference refidx="1"/>  </Para><Para id="_511">Childhood malignant ovarian GCTs can be divided into germinomatous (dysgerminomas) and nongerminomatous malignant GCTs (i.e., yolk sac carcinomas, mixed GCTs, choriocarcinoma, and embryonal carcinomas). </Para><Para id="_513">(Refer to the <SummaryRef href="CDR0000062854#_217" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Mature Teratomas [Nonsacrococcygeal Sites]</SummaryRef> section of this summary for more information about childhood mature and immature teratomas arising in the ovary and the PDQ summary on <SummaryRef href="CDR0000062935" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Ovarian Germ Cell Tumors Treatment</SummaryRef> for more information about the treatment of ovarian GCT in postpubertal females.)</Para><SummarySection id="_423"><Title>Dysgerminomas  of the ovary</Title><SummarySection id="_514"><Title>Standard treatment options for dysgerminomas of the ovary</Title><Para id="_515">Standard treatment options for dysgerminomas of the ovary include the following:</Para><OrderedList id="_516" Style="Arabic"><ListItem><SummaryRef href="CDR0000062854#_538" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_541" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (stages II through IV)</SummaryRef>.</ListItem></OrderedList><Para id="_517">The treatment options for dysgerminomas of the ovary differ by stage of disease.</Para><SummarySection id="_538"><Title>Stage I</Title><Para id="_539">For stage I ovarian dysgerminomas of the ovary, cure can usually be achieved by unilateral salpingo-oophorectomy, conserving the uterus and opposite ovary, and close follow-up observation.<Reference refidx="8"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/></Para><Para id="_540">Chemotherapy may be given if tumor markers do not normalize or if the tumor recurs.</Para></SummarySection><SummarySection id="_541"><Title>Stages II through IV</Title><Para id="_542">While advanced-stage ovarian dysgerminomas, like testicular seminomas, are highly curable with surgery and radiation therapy, the effects on growth, fertility, and risk of treatment-induced second malignancy in these young patients <Reference refidx="20"/> <Reference refidx="21"/> make chemotherapy a more attractive adjunct to surgery.<Reference refidx="22"/><Reference refidx="23"/>  Complete tumor resection is the goal for advanced dysgerminomas; platinum-based chemotherapy can be given preoperatively to facilitate resection or postoperatively (after debulking surgery) to avoid mutilating surgical procedures.<Reference refidx="19"/>  This approach results in a high rate of cure and the preservation of menstrual function and fertility in most patients with dysgerminomas.<Reference refidx="22"/><Reference refidx="24"/></Para></SummarySection></SummarySection></SummarySection><SummarySection id="_424"><Title>Malignant nongerminomatous  ovarian GCTs</Title><Para id="_520">A multidisciplinary approach is essential for treatment of ovarian GCTs.  Various surgical subspecialists and the pediatric oncologist must be involved in clinical decisions. The surgical approach for pediatric ovarian GCTs is often guided by the hope that reproductive function can be preserved. </Para><SummarySection id="_521"><Title>Standard treatment options for malignant nongerminomatous ovarian GCTs</Title><Para id="_522">Standard treatment options for malignant nongerminomatous ovarian GCTs include the following:</Para><OrderedList id="_523" Style="Arabic"><ListItem><SummaryRef href="CDR0000062854#_545" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and observation (stage I)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_549" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery and chemotherapy (stage I and stages II through IV)</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_552" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Biopsy followed by chemotherapy and surgery (initially unresectable tumors)</SummaryRef>.</ListItem></OrderedList><Para id="_147">The treatment of ovarian malignant GCTs that are not dysgerminomas or immature teratomas generally involves surgical resection and adjuvant chemotherapy.<Reference refidx="25"/><Reference refidx="26"/>  </Para><Para id="_543">The role for surgery at diagnosis is age- and site-dependent and must be individualized. The use of laparoscopy in children with ovarian GCTs has not been well studied.</Para><Para id="_524">Pediatric surgical guidelines to determine stage I disease have been published.<Reference refidx="27"/> Adult surgical guidelines to determine stage are more extensive. (Refer to the <SummaryRef href="CDR0000062935#_8" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Stage Information for Ovarian Germ Cell Tumors</SummaryRef> section of the PDQ summary on <SummaryRef href="CDR0000062935" url="/types/ovarian/hp/ovarian-germ-cell-treatment-pdq">Ovarian Germ Cell Tumors Treatment</SummaryRef> for more information about staging of ovarian GCTs in postpubertal females.) Strict surgical staging guidelines need to be followed to determine true stage I disease. Historically, in both pediatric and adult studies, comprehensive staging guidelines have not been followed. If strict surgical staging guidelines are not followed, surgery followed by chemotherapy, rather than surgery followed by observation, is the standard treatment.<Reference refidx="8"/><Reference refidx="28"/> A goal of surgical therapy for pediatric GCTs is to preserve reproductive function. If conservative surgery is the choice, a high rate of cure can be obtained with adjuvant chemotherapy, and adherence to strict surgical guidelines is not necessary.<Reference refidx="29"/></Para><Para id="_544">Platinum-based chemotherapy regimens such as PEB or  JEB have been used successfully in children.<Reference refidx="8"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="16"/> BEP is a common regimen in young women with ovarian GCTs.<Reference refidx="30"/><Reference refidx="31"/> BEP differs from PEB with the addition of weekly bleomycin.  This approach results in a high rate of cure and the preservation of menstrual function and fertility in most patients with nondysgerminomas.<Reference refidx="26"/><Reference refidx="28"/> (Refer to <SummaryRef href="CDR0000062854#_156" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Table 5</SummaryRef> for more information about the dosing schedules for BEP, PEB, and JEB.)</Para><SummarySection id="_545"><Title>Stage I</Title><Para id="_546">When strict surgical staging guidelines are followed, surgery followed by observation may be an appropriate treatment choice.</Para><Para id="_525">Evidence (surgery and observation for stage I disease):</Para><OrderedList id="_526" Style="Arabic" Compact="No"><ListItem>In a Children's Oncology Group (COG) trial, 25 girls with stage I ovarian malignant GCTs were treated with surgery and observation.<Reference refidx="27"/><ItemizedList id="_527" Style="bullet" Compact="No"><ListItem>The 4-year EFS was 52%.</ListItem><ListItem>Relapse was detected in 12 patients by tumor marker elevation (mean time, 2 months). Eleven patients later underwent salvage therapy with three cycles of PEB. The 4-year OS was 96%.</ListItem></ItemizedList> </ListItem></OrderedList><Para id="_611">Similar results have been reported in other international pediatric trials, but the number of patients has been small.<Reference refidx="8"/></Para><Para id="_547">When strict surgical staging guidelines are not followed, surgery followed by chemotherapy is an appropriate treatment choice. Chemotherapy consists of four cycles of PEB.<Reference refidx="10"/><Reference refidx="11"/></Para><Para id="_529">Evidence (surgery and chemotherapy for stage I disease):</Para><OrderedList id="_548" Style="Arabic" Compact="No"><ListItem>A pediatric intergroup trial studied patients with ovarian GCTs (stages I–IV).<Reference refidx="10"/><Reference refidx="29"/><ItemizedList id="_615" Style="bullet"><ListItem>For stage I ovarian cancer, the EFS and OS rates were both 95.1%.</ListItem></ItemizedList></ListItem><ListItem>In a previous U.S. intergroup trial where there was incomplete adherence to surgical staging guidelines, all reported stage I patients were given adjuvant chemotherapy and survived.<Reference refidx="8"/><Reference refidx="28"/>   Patients had excellent survival with four cycles of PEB and conservative surgery.</ListItem></OrderedList></SummarySection><SummarySection id="_549"><Title>Stages II through IV</Title><Para id="_550">Surgery and chemotherapy with four to six cycles of standard PEB in younger girls <Reference refidx="10"/><Reference refidx="11"/> and BEP in postpubertal girls are considered standard treatments.<Reference refidx="30"/><Reference refidx="31"/> Patients with normalization of tumor markers are imaged after four cycles of PEB, and any residual tumor is removed. If the tumor is completely resected but the specimen contains viable tumor, two additional cycles of PEB can be given.<Reference refidx="11"/> Any persistent viable tumor that remains indicates that the treatment has failed.</Para><Para id="_551">Alternatively, surgery and chemotherapy with four to six cycles of JEB is also a treatment option (patients were all younger than 15 years).<Reference refidx="8"/></Para></SummarySection><SummarySection id="_552"><Title>Initially unresectable tumor</Title><Para id="_553">Primary resection of ovarian GCT is usually attempted. In rare instances where primary resection of the ovary is not possible without undue risk of damage to adjacent structures, an appropriate strategy is biopsy for diagnosis followed by subsequent surgery in patients who have residual masses after undergoing chemotherapy.</Para></SummarySection></SummarySection></SummarySection><SummarySection id="_TrialSearch_70_sid_3"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_70_20">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43496&amp;tt=1&amp;format=2&amp;cn=1">childhood malignant ovarian germ cell tumor</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_70_21">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1">Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649. <ExternalRef xref="http://seer.cancer.gov/publications/childhood/">Also available online.</ExternalRef> Last accessed May 26, 2015.</Citation><Citation idx="2" PMID="16904461">Walsh TJ, Grady RW, Porter MP, et al.: Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology 68 (2): 402-5; discussion 405, 2006.</Citation><Citation idx="3" PMID="12632342" MedlineID="22519191">Schlatter M, Rescorla F, Giller R, et al.: Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg 38 (3): 319-24; discussion 319-24, 2003.</Citation><Citation idx="4">Canning DA: Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group [Editorial Comment on Schlatter]. J Urol  174 (1): 310, 2005.</Citation><Citation idx="5" PMID="9988869">Rescorla FJ: Pediatric germ cell tumors. Semin Surg Oncol 16 (2): 144-58, 1999.</Citation><Citation idx="6" PMID="7521931" MedlineID="94366361">Haas RJ, Schmidt P, Göbel U, et al.: Treatment of malignant testicular tumors in childhood: results of the German National Study 1982-1992. Med Pediatr Oncol 23 (5): 400-5, 1994.</Citation><Citation idx="7" PMID="9291812" MedlineID="97437279">Pinkerton CR: Malignant germ cell tumours in childhood. Eur J Cancer 33 (6): 895-901; discussion 901-2, 1997.</Citation><Citation idx="8" PMID="11078494" MedlineID="20530736">Mann JR, Raafat F, Robinson K, et al.: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (22): 3809-18, 2000.</Citation><Citation idx="9" PMID="24158884">Göbel U, Haas R, Calaminus G, et al.: Testicular germ cell tumors in boys &lt;10 years: results of the protocol MAHO 98 in respect to surgery and watch &amp; wait strategy. Klin Padiatr 225 (6): 296-302, 2013.</Citation><Citation idx="10" PMID="15337806">Rogers PC, Olson TA, Cullen JW, et al.: Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22 (17): 3563-9, 2004.</Citation><Citation idx="11" PMID="15226336">Cushing B, Giller R, Cullen JW, et al.: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22 (13): 2691-700, 2004.</Citation><Citation idx="12" PMID="17158533">de Wit R, Fizazi K: Controversies in the management of clinical stage I testis cancer. J Clin Oncol 24 (35): 5482-92, 2006.</Citation><Citation idx="13" PMID="17261854">Carver BS, Shayegan B, Serio A, et al.: Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol 25 (9): 1033-7, 2007.</Citation><Citation idx="14" PMID="17906201">Carver BS, Shayegan B, Eggener S, et al.: Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 25 (28): 4365-9, 2007.</Citation><Citation idx="15" PMID="19561445">Guo CC, Punar M, Contreras AL, et al.: Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol 33 (8): 1173-8, 2009.</Citation><Citation idx="16" PMID="10708940">Baranzelli MC, Bouffet E, Quintana E, et al.: Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer 36 (3): 376-83, 2000.</Citation><Citation idx="17" PMID="9053485" MedlineID="97178752">Dark GG, Bower M, Newlands ES, et al.: Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15 (2): 620-4, 1997.</Citation><Citation idx="18" PMID="10561269" MedlineID="20029998">Marina NM, Cushing B, Giller R, et al.: Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 17 (7): 2137-43, 1999.</Citation><Citation idx="19" PMID="8091071" MedlineID="94377822">Gershenson DM: Chemotherapy of ovarian germ cell tumors and sex cord stromal tumors. Semin Surg Oncol 10 (4): 290-8, 1994 Jul-Aug.</Citation><Citation idx="20" PMID="8177140" MedlineID="94232077">Teinturier C, Gelez J, Flamant F, et al.: Pure dysgerminoma of the ovary in childhood: treatment results and sequelae. Med Pediatr Oncol 23 (1): 1-7, 1994.</Citation><Citation idx="21" PMID="1991256" MedlineID="91121372">Mitchell MF, Gershenson DM, Soeters RP, et al.: The long-term effects of radiation therapy on patients with ovarian dysgerminoma. Cancer 67 (4): 1084-90, 1991.</Citation><Citation idx="22" PMID="10561340" MedlineID="20030069">Brewer M, Gershenson DM, Herzog CE, et al.: Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17 (9): 2670-75, 1999.</Citation><Citation idx="23" PMID="1719142" MedlineID="92044708">Williams SD, Blessing JA, Hatch KD, et al.: Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 9 (11): 1950-5, 1991.</Citation><Citation idx="24" PMID="2828558" MedlineID="88117650">Gershenson DM: Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 6 (2): 270-5, 1988.</Citation><Citation idx="25" PMID="1690272" MedlineID="90188473">Gershenson DM, Morris M, Cangir A, et al.: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8 (4): 715-20, 1990.</Citation><Citation idx="26" PMID="10326703" MedlineID="99256635">Mitchell PL, Al-Nasiri N, A'Hern R, et al.: Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer 85 (10): 2232-44, 1999.</Citation><Citation idx="27" PMID="24395845">Billmire DF, Cullen JW, Rescorla FJ, et al.: Surveillance after initial surgery for pediatric and adolescent girls with stage I ovarian germ cell tumors: report from the Children's Oncology Group. J Clin Oncol 32 (5): 465-70, 2014.</Citation><Citation idx="28" PMID="18948812">Palenzuela G, Martin E, Meunier A, et al.: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg 248 (5): 836-41, 2008.</Citation><Citation idx="29" PMID="15017564">Billmire D, Vinocur C, Rescorla F, et al.: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 39 (3): 424-9; discussion 424-9, 2004.</Citation><Citation idx="30" PMID="9633853">Williams SD: Ovarian germ cell tumors: an update. Semin Oncol 25 (3): 407-13, 1998.</Citation><Citation idx="31" PMID="7512129" MedlineID="94201785">Williams S, Blessing JA, Liao SY, et al.: Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 12 (4): 701-6, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_75"><SectMetaData><SpecificDiagnosis ref="CDR0000043497">childhood extragonadal germ cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Malignant Extragonadal   Extracranial GCTs in Children</Title><Para id="_76">Extragonadal extracranial germ cell tumors (GCTs) (i.e., sacrococcygeal, mediastinal, and retroperitoneal) are more common in children than in adults.<Reference refidx="1"/> Children with extragonadal 
malignant GCTs, particularly those with advanced-stage disease, have the
highest risk of treatment failure for any GCT presentation.<Reference refidx="2"/><Reference refidx="3"/> </Para><Para id="_554">In a study of prognostic factors in pediatric extragonadal malignant GCTs, age older than 12 years was the most important prognostic factor. In a multivariate analysis, children aged 12 years or older with thoracic tumors had six times the risk of death compared with children younger than 12 years with primary nonthoracic tumors.<Reference refidx="4"/> </Para><SummarySection id="_555"><Title>Standard Treatment Options for Malignant Extragonadal Extracranial GCTs </Title><Para id="_556">Standard treatment options for malignant extragonadal extracranial GCTs include the following:</Para><OrderedList id="_585" Style="Arabic"><ListItem>Surgery and chemotherapy.</ListItem><ListItem>Biopsy followed by chemotherapy and possibly surgery.</ListItem></OrderedList><Para id="_558">Outcome  has improved remarkably since the advent of platinum-based
chemotherapy and the use of a multidisciplinary treatment approach.<Reference refidx="2"/><Reference refidx="5"/>  Complete resection before chemotherapy may be possible in
some patients without major morbidity. For  patients  with
locally advanced sacrococcygeal tumors, mediastinal tumors,  or large pelvic tumors, tumor biopsy followed by preoperative chemotherapy can facilitate subsequent complete tumor resection and improve ultimate patient outcome.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_559">The role for surgery at diagnosis for extragonadal tumors is age- and site-dependent and must be individualized. Depending on the clinical setting, the appropriate surgical approach may be primary resection,  biopsy before chemotherapy, or no surgery (e.g., mediastinal primary tumor in a patient with a compromised airway and elevated tumor markers). An appropriate strategy may be biopsy at diagnosis followed by chemotherapy and subsequent surgery in selected patients who have residual masses after chemotherapy.</Para><SummarySection id="_560"><Title>Stages I and II</Title><Para id="_561">Surgery and chemotherapy with four to six cycles of standard cisplatin, etoposide, and bleomycin (PEB) is one treatment alternative. Patients treated with this regimen have an overall survival (OS) outcome greater than 90%, suggesting that a reduction in therapy could be considered.<Reference refidx="2"/><Reference refidx="9"/> An alternative treatment option is surgery and chemotherapy with six cycles of carboplatin, etoposide, and bleomycin (JEB).<Reference refidx="5"/></Para></SummarySection><SummarySection id="_562"><Title>Stages III and IV</Title><Para id="_563">A treatment option for stage III and  stage IV disease is surgery and chemotherapy with four to six cycles of standard PEB. Patients have an OS outcome approaching 80% with this regimen.<Reference refidx="2"/> Another treatment option is surgery and chemotherapy with six cycles of JEB, which has an OS similar to that of the PEB regimen.<Reference refidx="5"/></Para><Para id="_564">A Children's Oncology Group trial investigated the addition of cyclophosphamide to standard-dose PEB. The addition of cyclophosphamide was feasible and well tolerated at all dose levels, but there was no evidence that adding cyclophosphamide improves efficacy.<Reference refidx="10"/></Para></SummarySection></SummarySection><SummarySection id="_565"><Title>Malignant Extragonadal Extracranial GCTs (Sacrococcygeal Sites)</Title><Para id="_148">Sacrococcygeal GCTs are common extragonadal tumors that occur in very young children, predominantly young females.<Reference refidx="11"/>  The tumors are usually diagnosed at birth, when large external lesions predominate (usually mature or immature teratomas), or later in the first years of life, when presacral lesions with higher malignancy rates predominate.<Reference refidx="11"/></Para><Para id="_569">Malignant sacrococcygeal tumors are usually very advanced at diagnosis; two-thirds of patients have locoregional disease, and metastases are present in 50% of patients.<Reference refidx="7"/><Reference refidx="12"/><Reference refidx="13"/> Because of their advanced stage at presentation, the management of sacrococcygeal tumors requires a multimodal approach with platinum-based chemotherapy followed by delayed tumor resection. </Para><Para id="_570">Platinum-based therapies, with either cisplatin or carboplatin, are the cornerstone of treatment. The PEB regimen or the JEB regimen produces event-free survival (EFS) rates of 75% to 85% and  OS rates of 80% to 90%.<Reference refidx="7"/><Reference refidx="8"/>  Surgery may be facilitated by preoperative chemotherapy. In any patient with a sacrococcygeal GCT, resection of the coccyx is mandatory.<Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_571"> Completeness of surgical resection is an important prognostic factor, as shown in the following circumstances:<Reference refidx="7"/><Reference refidx="8"/></Para><ItemizedList id="_572" Style="bullet"><ListItem>Resected tumors with negative microscopic margins—EFS rates higher than 90%.</ListItem><ListItem>Resected tumors with microscopic margins—EFS rates of 75% to 85%.</ListItem><ListItem>Resected tumors with macroscopic residual disease—EFS rates lower than 40%. </ListItem></ItemizedList></SummarySection><SummarySection id="_566"><Title>Malignant Extragonadal Extracranial GCTs (Mediastinal)</Title><Para id="_77">Mediastinal GCTs account for 15% to 20% of malignant extragonadal
extracranial GCTs in children.<Reference refidx="5"/> The histology of mediastinal
GCT is dependent on age, with teratomas predominating among
infants and yolk sac tumor histology predominating among children aged 1
to 4 years.<Reference refidx="6"/>  </Para><Para id="_573">Children with mediastinal teratomas are treated with tumor
resection, which is curative in almost all patients.<Reference refidx="6"/> Children with
malignant, nonmetastatic mediastinal GCTs who receive 
cisplatin-based chemotherapy have 5-year EFS and OS rates of 90%; however, metastatic mediastinal tumors have an EFS closer to 70%.<Reference refidx="5"/><Reference refidx="6"/> </Para><Para id="_574">Most mediastinal GCTs in adolescents and young adults occur in males, and 22% to 50% have cytogenetic changes consistent with Klinefelter syndrome.<Reference refidx="14"/><Reference refidx="15"/> The age of  presentation is younger in patients with Klinefelter syndrome.<Reference refidx="14"/><Reference refidx="15"/>   As with sacrococcygeal tumors, primary chemotherapy is usually necessary to facilitate surgical resection of mediastinal GCTs, and the completeness of resection is a very important prognostic indicator.<Reference refidx="6"/><Reference refidx="16"/>  Survival rates for the older adolescent and young adult
population with mediastinal tumors are  generally  lower than 60%.<Reference refidx="4"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/>; <Reference refidx="20"/>[<LOERef href="CDR0000335144">Level of evidence: 3iiA</LOERef>] </Para><Para id="_575">Patients with a malignant mediastinal primary tumor and extracranial metastases are at the highest risk of developing brain metastases and are monitored closely for signs and symptoms of central nervous system involvement.<Reference refidx="21"/>[<LOERef href="CDR0000335145">Level of evidence: 3iiB</LOERef>] (Refer to the PDQ summary on <SummaryRef href="CDR0000062939" url="/types/extragonadal-germ-cell/hp/extragonadal-treatment-pdq">Extragonadal Germ Cell
Tumors Treatment</SummaryRef> for more information about the treatment of adult patients.)
</Para></SummarySection><SummarySection id="_567"><Title>Malignant Extragonadal Extracranial GCTs (Retroperitoneum)</Title><Para id="_149">Malignant GCTs located in the retroperitoneum or abdomen usually present in children younger than 5 years; most tumors are advanced stage and locally unresectable at diagnosis.<Reference refidx="22"/> A limited biopsy followed by platinum-based chemotherapy to shrink tumor bulk can lead to complete tumor resection in most patients.  Despite the advanced-stage disease in most patients, the 6-year  EFS using PEB was 83% in the Pediatric Oncology Group/Children's Cancer Group intergroup study.<Reference refidx="22"/></Para></SummarySection><SummarySection id="_568"><Title>Malignant Extragonadal Extracranial GCTs (Head and Neck Sites)</Title><Para id="_326">Although rare, benign and malignant GCTs can occur in the head and neck region, especially in infants. The airway is often threatened. Surgery for nonmalignant tumors and surgery plus chemotherapy for malignant tumors can be curative.<Reference refidx="23"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]</Para></SummarySection><SummarySection id="_TrialSearch_75_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_75_20">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43497&amp;tt=1&amp;format=2&amp;cn=1">childhood extragonadal germ cell tumor</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_75_21">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1271542">Pantoja E, Llobet R, Gonzalez-Flores B: Retroperitoneal teratoma: historical review. J Urol 115 (5): 520-3, 1976.</Citation><Citation idx="2" PMID="15226336">Cushing B, Giller R, Cullen JW, et al.: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22 (13): 2691-700, 2004.</Citation><Citation idx="3" PMID="10561181" MedlineID="20029910">Baranzelli MC, Kramar A, Bouffet E, et al.: Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. J Clin Oncol 17 (4): 1212, 1999.</Citation><Citation idx="4" PMID="16735707">Marina N, London WB, Frazier AL, et al.: Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol 24 (16): 2544-8, 2006.</Citation><Citation idx="5" PMID="11078494" MedlineID="20530736">Mann JR, Raafat F, Robinson K, et al.: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (22): 3809-18, 2000.</Citation><Citation idx="6" PMID="10673525" MedlineID="20139488">Schneider DT, Calaminus G, Reinhard H, et al.: Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. J Clin Oncol 18 (4): 832-9, 2000.</Citation><Citation idx="7" PMID="11283126">Göbel U, Schneider DT, Calaminus G, et al.: Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 19 (7): 1943-50, 2001.</Citation><Citation idx="8" PMID="11150431" MedlineID="20584362">Rescorla F, Billmire D, Stolar C, et al.: The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882). J Pediatr Surg 36 (1): 12-7, 2001.</Citation><Citation idx="9" PMID="15337806">Rogers PC, Olson TA, Cullen JW, et al.: Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22 (17): 3563-9, 2004.</Citation><Citation idx="10" PMID="23703725">Malogolowkin MH, Krailo M, Marina N, et al.: Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG). Pediatr Blood Cancer 60 (10): 1602-5, 2013.</Citation><Citation idx="11" PMID="4843993">Altman RP, Randolph JG, Lilly JR: Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 9 (3): 389-98, 1974.</Citation><Citation idx="12" PMID="9498381">Rescorla FJ, Sawin RS, Coran AG, et al.: Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 33 (2): 171-6, 1998.</Citation><Citation idx="13" PMID="12610174">Calaminus G, Schneider DT, Bökkerink JP, et al.: Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. J Clin Oncol 21 (5): 781-6, 2003.</Citation><Citation idx="14" PMID="3040921" MedlineID="87310573">Nichols CR, Heerema NA, Palmer C, et al.: Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 5 (8): 1290-4, 1987.</Citation><Citation idx="15" PMID="11921289" MedlineID="21917062">Schneider DT, Schuster AE, Fritsch MK, et al.: Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents. Genes Chromosomes Cancer 34 (1): 115-25, 2002.</Citation><Citation idx="16" PMID="11150432" MedlineID="20584363">Billmire D, Vinocur C, Rescorla F, et al.: Malignant mediastinal germ cell tumors: an intergroup study. J Pediatr Surg 36 (1): 18-24, 2001.</Citation><Citation idx="17" PMID="11157018" MedlineID="21104116">Vuky J, Bains M, Bacik J, et al.: Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 19 (3): 682-8, 2001.</Citation><Citation idx="18" PMID="10699894" MedlineID="20164351">Ganjoo KN, Rieger KM, Kesler KA, et al.: Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer 88 (5): 1051-6, 2000.</Citation><Citation idx="19" PMID="11919246" MedlineID="21917884">Bokemeyer C, Nichols CR, Droz JP, et al.: Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 20 (7): 1864-73, 2002.</Citation><Citation idx="20" PMID="18222229">Kang CH, Kim YT, Jheon SH, et al.: Surgical treatment of malignant mediastinal nonseminomatous germ cell tumor. Ann Thorac Surg 85 (2): 379-84, 2008.</Citation><Citation idx="21" PMID="22693072">Göbel U, von Kries R, Teske C, et al.: Brain metastases during follow-up of children and adolescents with extracranial malignant germ cell tumors: risk adapted management decision tree analysis based on data of the MAHO/MAKEI-registry. Pediatr Blood Cancer 60 (2): 217-23, 2013.</Citation><Citation idx="22" PMID="12632341">Billmire D, Vinocur C, Rescorla F, et al.: Malignant retroperitoneal and abdominal germ cell tumors: an intergroup study. J Pediatr Surg 38 (3): 315-8; discussion 315-8, 2003.</Citation><Citation idx="23" PMID="18937314">Bernbeck B, Schneider DT, Bernbeck B, et al.: Germ cell tumors of the head and neck: report from the MAKEI Study Group. Pediatr Blood Cancer 52 (2): 223-6, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_79"><SectMetaData><SpecificDiagnosis ref="CDR0000043498">recurrent childhood malignant germ cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment of Recurrent Malignant  GCTs in Children</Title><Para id="_150">Only a small number of children and adolescents with extracranial germ cell tumors (GCTs) have a recurrence.<Reference refidx="1"/><Reference refidx="2"/> However, the approach to the treatment of recurrent disease and its success depend on the initial treatment regimen and on the response of the tumor  to treatment.  </Para><Para id="_425">There are no standard treatment options for recurrent pediatric GCTs.  Information about ongoing clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</ExternalRef>.</Para><SummarySection id="_576"><Title>Treatment Options for Recurrent Malignant GCTs in Children</Title><Para id="_426">Treatment options for recurrent childhood malignant GCTs include the following:</Para><OrderedList id="_586" Style="Arabic"><ListItem>Surgery only.</ListItem><ListItem><SummaryRef href="CDR0000062854#_428" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Surgery followed by chemotherapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_429" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Chemotherapy followed by surgery and possibly radiation therapy</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_613" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">High-dose (HD) chemotherapy and hematopoietic stem cell rescue</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062854#_580" url="/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">Radiation therapy followed by surgery (for brain metastases)</SummaryRef>.</ListItem></OrderedList><Para id="_153">Despite overall cure rates higher than 80%, children with extracranial GCTs who have disease recurrence after surgery and three-agent, platinum-based combination chemotherapy (cisplatin, etoposide, and bleomycin [PEB]  or carboplatin, etoposide, and bleomycin [JEB]) have an unfavorable prognosis.  Reports regarding the treatment and outcome of these children are based on small studies.<Reference refidx="3"/>  </Para><Para id="_264">Reports of salvage treatment strategies used in adult recurrent GCTs  include larger numbers of patients, but the differences between children and adults regarding the location of the primary  GCT site, pattern of relapse, and the biology of childhood  GCTs may limit the applicability of adult salvage approaches to children. In adults with recurrent GCTs, several chemotherapy combinations have achieved relatively good disease-free status.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/>  A combination of paclitaxel and gemcitabine has demonstrated activity in adults with testicular GCTs who relapsed after HD chemotherapy and hematopoietic stem cell transplant (HSCT).<Reference refidx="10"/></Para><SummarySection id="_428"><Title>Surgery followed by chemotherapy</Title><Para id="_151">If a tumor recurs, boys with stage I testicular disease originally treated with surgical resection and observation can usually undergo salvage therapy with  further surgical excision and standard PEB or JEB chemotherapy.<Reference refidx="11"/><Reference refidx="12"/>   </Para><Para id="_579">For stage I ovarian GCT patients originally treated with surgery and observation, several European studies have reported encouraging salvage rates with further surgical excision and chemotherapy.<Reference refidx="13"/><Reference refidx="14"/></Para><Para id="_612">In a Children’s Oncology Group trial (<ProtocolRef href="CDR0000542424" nct_id="NCT00467051">AGCT0521 [NCT00467051]</ProtocolRef>), patients who relapsed after PEB therapy received two cycles of paclitaxel, ifosfamide, and carboplatin. Study results are pending.</Para></SummarySection><SummarySection id="_429"><Title>Chemotherapy followed by surgery and possibly radiation therapy</Title><Para id="_152">Most children with benign sacrococcygeal tumors experience  recurrence with a malignant component at the primary tumor site. For these children, complete surgical resection of the recurrent tumor and  coccyx (if not done originally) is the basis of salvage treatment; preoperative chemotherapy with PEB  may assist the surgical resection. In patients who had a malignant sacrococcygeal tumor that recurred after PEB treatment, surgery and additional chemotherapy may be warranted; when a complete salvage resection is not achieved, postoperative local radiation therapy may be an option.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_613"><Title>HD chemotherapy and hematopoietic stem cell rescue</Title><Para id="_616">The role of HD chemotherapy and hematopoietic stem cell rescue for recurrent pediatric GCTs is not established, despite anecdotal reports. (Refer to the <SummaryRef href="CDR0000700000#_163" url="/types/childhood-cancers/child-hct-hp-pdq">Autologous Hematopoietic Cell Transplantation</SummaryRef> section of the PDQ summary on  <SummaryRef href="CDR0000700000" url="/types/childhood-cancers/child-hct-hp-pdq">Childhood Hematopoietic Cell Transplantation</SummaryRef>  for more information about transplantation.) In one European series, 10 of 23 children with relapsed extragonadal GCTs achieved long-term disease-free survival (median follow-up, 66 months) after receiving HD chemotherapy with stem cell support.<Reference refidx="15"/>  Further study in children and adolescents is needed.</Para><Para id="_614">HD chemotherapy with autologous stem cell rescue has been explored as a treatment for adults with recurrent testicular GCTs. HD chemotherapy plus hematopoietic stem cell rescue has been reported to cure adult patients with relapsed testicular GCTs, even as third-line therapy and in cisplatin-refractory patients.<Reference refidx="16"/>   While several other studies support this approach,<Reference refidx="10"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/> others do not.<Reference refidx="21"/><Reference refidx="22"/> Salvage attempts using HD-chemotherapy regimens may be of little benefit if the patient is not clinically disease free at the time of HSCT.<Reference refidx="16"/><Reference refidx="23"/></Para></SummarySection><SummarySection id="_580"><Title>Radiation therapy followed by surgery (for brain metastases)</Title><Para id="_581"> Patients with nongerminomatous brain metastases may respond to radiation therapy. In the German Maligne Keimzelltümoren (MAKEI) studies, radiation therapy and surgery for patients with brain metastases provided palliation and occasional long-term survival.<Reference refidx="24"/><Reference refidx="25"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</Para></SummarySection></SummarySection><SummarySection id="_431"><SectMetaData><SpecificDiagnosis ref="CDR0000043498">recurrent childhood malignant germ cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Treatment Options Under Clinical Evaluation for Recurrent Malignant GCTs in Children</Title><Para id="_582">Treatment options under clinical evaluation for recurrent malignant GCTs in children include the following:</Para><OrderedList id="_590" Style="Arabic" Compact="No"><ListItem>Hyperthermia. A single-institution study of 44 young people (aged 7 months to 21 years) with refractory or recurrent extracranial GCTs, using cisplatin/etoposide/ifosfamide and regional deep hyperthermia with or without surgery plus radiation therapy for residual tumor, showed a response rate of 86% in 35 patients for whom sufficient data were available. The 5-year  event-free survival was 62%, and the 5-year overall survival was 72%.<Reference refidx="26"/>[<LOERef href="CDR0000335147">Level of evidence: 3iiDi</LOERef>] However, regional hyperthermia facilities are limited and not readily available for children in the United States.  Further study in children and adolescents is needed.</ListItem></OrderedList><Para id="_640">Information about ongoing clinical trials is available from the <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</ExternalRef>.</Para><SummarySection id="_TrialSearch_431_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_431_20">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43498&amp;tt=1&amp;format=2&amp;cn=1">recurrent childhood malignant germ cell tumor</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_431_21">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection></SummarySection><ReferenceSection><Citation idx="1" PMID="11078494" MedlineID="20530736">Mann JR, Raafat F, Robinson K, et al.: The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol 18 (22): 3809-18, 2000.</Citation><Citation idx="2" PMID="15226336">Cushing B, Giller R, Cullen JW, et al.: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 22 (13): 2691-700, 2004.</Citation><Citation idx="3" PMID="11283127">Schneider DT, Wessalowski R, Calaminus G, et al.: Treatment of recurrent malignant sacrococcygeal germ cell tumors: analysis of 22 patients registered in the German protocols MAKEI 83/86, 89, and 96. J Clin Oncol 19 (7): 1951-60, 2001.</Citation><Citation idx="4" PMID="9667270" MedlineID="98329844">Loehrer PJ Sr, Gonin R, Nichols CR, et al.: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16 (7): 2500-4, 1998.</Citation><Citation idx="5" PMID="10856101">Motzer RJ, Sheinfeld J, Mazumdar M, et al.: Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18 (12): 2413-8, 2000.</Citation><Citation idx="6" PMID="11250992">Hartmann JT, Einhorn L, Nichols CR, et al.: Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 19 (6): 1641-8, 2001.</Citation><Citation idx="7" PMID="9543060" MedlineID="98202059">Mandanas RA, Saez RA, Epstein RB, et al.: Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors. Bone Marrow Transplant 21 (6): 569-76, 1998.</Citation><Citation idx="8" PMID="17194908">Kondagunta GV, Bacik J, Sheinfeld J, et al.: Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 25 (1): 85-90, 2007.</Citation><Citation idx="9" PMID="14568987">Schmoll HJ, Kollmannsberger C, Metzner B, et al.: Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21 (22): 4083-91, 2003.</Citation><Citation idx="10" PMID="17290059">Einhorn LH, Brames MJ, Juliar B, et al.: Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 25 (5): 513-6, 2007.</Citation><Citation idx="11" PMID="12632342" MedlineID="22519191">Schlatter M, Rescorla F, Giller R, et al.: Excellent outcome in patients with stage I germ cell tumors of the testes: a study of the Children's Cancer Group/Pediatric Oncology Group. J Pediatr Surg 38 (3): 319-24; discussion 319-24, 2003.</Citation><Citation idx="12" PMID="15337806">Rogers PC, Olson TA, Cullen JW, et al.: Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol 22 (17): 3563-9, 2004.</Citation><Citation idx="13" PMID="10708940">Baranzelli MC, Bouffet E, Quintana E, et al.: Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer 36 (3): 376-83, 2000.</Citation><Citation idx="14" PMID="9053485" MedlineID="97178752">Dark GG, Bower M, Newlands ES, et al.: Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15 (2): 620-4, 1997.</Citation><Citation idx="15" PMID="16106248">De Giorgi U, Rosti G, Slavin S, et al.: Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 93 (4): 412-7, 2005.</Citation><Citation idx="16" PMID="17652649">Einhorn LH, Williams SD, Chamness A, et al.: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357 (4): 340-8, 2007.</Citation><Citation idx="17" PMID="11013274" MedlineID="20469575">Bhatia S, Abonour R, Porcu P, et al.: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18 (19): 3346-51, 2000.</Citation><Citation idx="18" PMID="10715285" MedlineID="20181879">Motzer RJ, Mazumdar M, Sheinfeld J, et al.: Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18 (6): 1173-80, 2000.</Citation><Citation idx="19" PMID="11134198">Rick O, Bokemeyer C, Beyer J, et al.: Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19 (1): 81-8, 2001.</Citation><Citation idx="20" PMID="20194867">Feldman DR, Sheinfeld J, Bajorin DF, et al.: TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 28 (10): 1706-13, 2010.</Citation><Citation idx="21" PMID="11374323">Beyer J, Rick O, Siegert W, et al.: Salvage chemotherapy in relapsed germ cell tumors. World J Urol 19 (2): 90-3, 2001.</Citation><Citation idx="22" PMID="8874322" MedlineID="97028308">Beyer J, Kramar A, Mandanas R, et al.: High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14 (10): 2638-45, 1996.</Citation><Citation idx="23" PMID="15365067">Rick O, Bokemeyer C, Weinknecht S, et al.: Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. J Clin Oncol 22 (18): 3713-9, 2004.</Citation><Citation idx="24" PMID="22693072">Göbel U, von Kries R, Teske C, et al.: Brain metastases during follow-up of children and adolescents with extracranial malignant germ cell tumors: risk adapted management decision tree analysis based on data of the MAHO/MAKEI-registry. Pediatr Blood Cancer 60 (2): 217-23, 2013.</Citation><Citation idx="25" PMID="20514616">Göbel U, Schneider DT, Teske C, et al.: Brain metastases in children and adolescents with extracranial germ cell tumor - data of the MAHO/MAKEI-registry. Klin Padiatr 222 (3): 140-4, 2010.</Citation><Citation idx="26" PMID="23823158">Wessalowski R, Schneider DT, Mils O, et al.: Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol 14 (9): 843-52, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_112"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (06/17/2015)</Title><Para id="_116">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_639">This summary was reformatted.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/pediatric-treatment-board">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062854#_AboutThis_1" url="http://www.cancer.gov/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood extracranial germ cell tumors. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/pediatric-treatment-board">PDQ Pediatric Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Childhood Extracranial Germ Cell Tumors Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Thomas A. Olson, MD (AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus)</ListItem><ListItem>R Beverly Raney, MD (Consultant)</ListItem><ListItem>Stephen J. Shochat, MD (St. Jude Children's Research Hospital)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Childhood Extracranial Germ Cell Tumors Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq">http://www.cancer.gov/types/extracranial-germ-cell/hp/germ-cell-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-06-17</DateLastModified></Summary>
